## Table of contents:

Supplementary text files
S1 Text. Supplementary methods: Exposure assessment and calculation of trend
S2 Text. Supplementary methods: Data collection of covariates
Supplementary Tables11
S1 Table. Baseline distribution of meat intake of included UK Biobank participants11
S2 Table. Baseline characteristics by red and processed meat intake12
S3 Table. Baseline characteristics by poultry intake15
S4 Table. Hazard ratios and 95% confidence intervals of cancer incidence by site according to total meat intake in UK Biobank
S5 Table. Hazard ratios and 95% confidence intervals of cancer incidence by site according to red and processed meat intake in UK Biobank21
S6 Table. Hazard ratios and 95% confidence intervals of cancer incidence by site according to red meat intake in UK Biobank24
S7 Table. Hazard ratios and 95% confidence intervals of cancer incidence by site according to processed meat intake in UK Biobank27
S8 Table. Hazard ratios and 95% confidence intervals of cancer incidence by site according to poultry intake in UK Biobank
S9 Table. Multivariable adjusted hazard ratios and 95% confidence intervals of colorectal, colon and rectal cancer incidence by meat type and sex in UK Biobank*
Supplementary figures
S1 Fig. Associations of total meat intake and cancer incidence by cancer site (per 100g/day) when excluding first 2 years of follow-up (A, n = 459,363) and including only never smokers (B, n = 256,009)*
S2 Fig. Associations of red and processed meat intake and cancer incidence by cancer site (per 70g/day) when excluding first 2 years of follow-up (A, n = $459,713$ ) and including only never smokers (B, n = $256,182$ )*
S3 Fig. Associations of red meat intake and cancer incidence by cancer site (per 50g/day) when excluding first 2 years of follow-up (A, n = 460,288) and including only never smokers (B, n = 256,545)*
S4 Fig. Associations of processed meat intake and cancer incidence by cancer site (per 20g/day) when excluding first 2 years of follow-up (A, n = 464,736) and including only never smokers (B, n = 258,827)*

S5 Fig. Associations of poultry intake and cancer incidence by cancer site (per 30g/day) when
excluding first 2 years of follow-up (A, $n = 464,897$ ) and including only never smokers (B,
n = 259,040)*

#### Supplementary text files

#### S1 Text. Supplementary methods: Exposure assessment and calculation of trend

Information on meat intake was derived from five questions included in the touchscreen questionnaire: 'How often do you eat processed meats (such as bacon, ham, sausages, meat pies, kebabs, burgers, chicken nuggets)', 'How often do you eat chicken, turkey or other poultry? (Do not count processed meats)', 'How often do you eat beef? (Do not count processed meats)', 'How often do you eat beef? (Do not count processed meats)', 'How often do you eat beef? (Do not count processed meats)', 'How often do you eat beef? (Do not count processed meats)', 'How often do you eat lamb/mutton? (Do not count processed meats)' and 'How often do you eat pork? (Do not count processed meats such as bacon or ham)'. As described in the main manuscript, these were used to differentiate intakes of red, processed meat and poultry, and additionally combined to intakes of red and processed meat and total meat. Intakes were categorised into three to four groups depending on the distribution of the data.

To calculate a trend in risk the data from the touchscreen questionnaire was combined with data from a second diet questionnaire, the Oxford WebQ. In 2009 this additional questionnaire on dietary intake the day before was added to the data collection [1]. The Oxford WebQ is a self-administered webbased 24 hour recall questionnaire of frequency from a set food list (206 items) [2]. Participants recruited after introduction of the Oxford WebQ completed this questionnaire at the baseline assessment centre (n = 70,716). All participants who had agreed to being re-contacted by UK Biobank and had provided email addresses (approximately 320,000 participants) were invited to complete the Oxford WebQ online at home on 4 occasions during the follow-up period, February -April 2011, June – August 2011, October – December 2011 and April to June 2012 [3]. To obtain mean meat intake in each touchscreen intake group we selected a subsample of 69,076 participants, who had completed a minimum of three WebQ questionnaires to account for daily variation in diet, who did not suffer from any cancer (excluding non-melanoma skin cancer ICD-10 C44) when completing any of these questionnaires, and who had at no time reported energy intakes outside of 2,093 to 14,654 kJ for women, 3,349 to 16,747 kJ for men and unusual eating or drinking due to illness or fasting [4]. Meat items were chosen to closely match the touchscreen [5]. First, mean meat intake was averaged across WebQ questionnaires for each participant in the subsample. Second, the average meat intake of each touchscreen category was assigned to the participants of the subsample with re-measured 24-h dietary recall based on the WebQ [6]. This method was used to calculate a trend in risk per increment and reduce measurement error including regression dilution [7].

Trends in risk are expressed in increments of 50 g/day for red meat intake, 20 g/day for processed meat intake, 30 g/day for poultry intake, 70 g/day for red and processed meat intake and 100 g/day for total meat intake. Increments were chosen based on the approximate difference between mean intakes based on responses to the WebQ in the highest and the lowest categories for each meat-type in our cohort.

#### S2 Text. Supplementary methods: Data collection of covariates

Covariates were chosen based on the literature and availability of data at baseline.

## <u>Age:</u>

Age at recruitment was recorded at the reception when attending the baseline assessment centre. We then categorised age into 6 groups: <45, 45-<50, 50-<55, 55-<60, 60-<65 and ≥65 years.

## Region:

Region refers to the respective baseline assessment centres which were based in Barts, Hounslow, Croydon, Swansea, Wrexham, Cardiff, Stockport, Manchester, Liverpool, Bury, Newcastle upon Tyne, Middlesbrough, Leeds, Sheffield, Stoke, Birmingham, Nottingham, Oxford, Reading, Bristol, Glasgow, and Edinburgh. These regions were grouped as follows: London (Barts, Hounslow and Croydon), Wales (Wrexham, Swansea and Cardiff), North-West (Stockport, Manchester, Liverpool and Bury), North-East (Newcastle and Middlesbrough), Yorkshire and Humber (Leeds and Sheffield), West Midlands (Stoke and Birmingham), East Midlands (Nottingham), South-East (Oxford, Reading), South-West (Bristol) and Scotland (Glasgow and Edinburgh).

## Ethnicity:

Ethnicity was assessed using one overall question on ethnicity 'What is your ethnic group?' allowing for 'White', 'Mixed', 'Asian or Asian British', 'Black or Black British', 'Chinese', 'Other ethnic group', 'Do not know' or 'Prefer not to answer' and four supporting questions within groups. Ethnicity was categorised into 4 groups: 'White' was defined as either answering white, British, Irish or any other white background; 'Asian or Asian British' was defined as Asian or Asian British, Chinese, Indian, Pakistani, Bangladeshi or any other Asian background; 'Black or Black British' was defined as Black or Black British, Caribbean, African or any other Black background; 'Mixed Race or other' was defined as reporting either any other ethnic groups or mixed ethnicity; participants with missing data, reporting they did not know or preferred not to answer were grouped as 'unknown' (0.6%). An alternative variable with three categories ('White', 'Non-White' and 'unknown'), was used in analyses of cancer sites where there were no or too few cases in each ethnic group other than white (oral, oesophagus, stomach and melanoma skin cancer).

## Townsend deprivation score:

Material deprivation was measured with the Townsend index. Participants were assigned a score based on their postcode at assessment. The Townsend index is derived from four variables: percentage unemployment, percentage overcrowded households, percentage of people with no car ownership and percentage of non-home owners [8]. Negative values indicate areas with relative affluence with low material deprivation, positive indicate areas with high material deprivation [9]. For analyses the index was categorised into quintiles (Q1: mean -4.69, Q2: mean -3.34, Q3: mean -2.09, Q4: mean -0.09, Q5: mean 3.78). Participants without Townsend index information were categorised as 'unknown' (0.1%).

## Qualification:

Highest qualification was assessed within the touchscreen questionnaire 'Which of the following qualifications do you have?' with the options 'College or University degree', 'A levels/AS levels or equivalent', 'O levels/GCSEs or equivalent', 'CSEs or equivalent', 'NVQ or HND or HNC or

equivalent', 'Other professional qualifications e.g.: nursing, teaching', 'None of the above' and 'Prefer not to answer'. Qualification was then categorised into three groups: the highest qualifications included 'College or University degree', 'NVQ or HND or HNC or equivalent', 'Other professional qualifications e.g.: nursing, teaching' and are referred to as College or university degree/vocational qualification; the intermediate qualifications included 'A levels/AS levels or equivalent' and are referred to as national examination at age 17-18; and the lowest level of qualifications included 'O levels/GCSEs or equivalent', 'CSEs or equivalent' and are referred to as national examination at age 16. Participants who had answered 'None of the above' or 'prefer not to answer' or who had not answered the question were categorised as 'other/unknown' (18.7%).

## Employment:

Current employment status was assessed within the touchscreen questionnaire with the question 'Which of the following describes your current situation?' allowing for multiple answers: 'In paid employment or self-employed', 'Retired', 'Looking after home and/or family', 'Unable to work because of sickness or disability', 'Unemployed', 'Doing unpaid or voluntary work', 'Full or part time student', 'None of the above' and 'Prefer not to answer'. Participants who reported being in paid employment or self-employed were grouped into 'in paid employment', retired participants were grouped into 'pension', those reporting no paid employment (only reporting caring responsibilities, being a student, unemployed or inability to work) were grouped into 'not in paid employment' and participants who did not answer, preferred not to answer or deemed no answer to fit were grouped into an 'unknown' category (1.2%).

## Living with a spouse or partner:

Living with a partner was defined as having answered the question 'How are the other people who live with you related to you?' with 'Husband, wife or partner' within the touchscreen questionnaire. Participants with no information on this or who preferred not to answer were categorised as unknown (0.4%).

## Height:

Height was measured at baseline assessment with a Seca 240 cm height measure using a standardised protocol and categorised into sex-specific quintiles (Women: Q1: mean 154 cm, Q2: mean 160 cm, Q3: mean 163 cm, Q4: mean 166 cm, Q5: mean 172 cm; Men: Q1: mean 167 cm, Q2: mean 173 cm, Q3: mean 176 cm, Q4: mean 179 cm, Q5: mean 185 cm). Where height measurements were missing participants were categorised into an 'unknown' group (0.5%).

## Body mass index (BMI):

Weight was measured at baseline assessment using a Tanita BC418MA body composition analyser as part of Bioimpedance measurement. For participants that did not participate in Bioimpedance analysis body weight was based on measurement using a standard scale. Body mass index (BMI) was calculated as weight in kilograms divided by height in metres squared and categorised into sexspecific quintiles (Women: Q1: mean 21 kg/m<sup>2</sup>, Q2: mean 24 kg/m<sup>2</sup>, Q3: mean 26 kg/m<sup>2</sup>, Q4: mean 29 kg/m<sup>2</sup>, Q5: mean 35 kg/m<sup>2</sup>; Men: Q1: mean 23 kg/m<sup>2</sup>, Q2: mean 26 kg/m<sup>2</sup>, Q3: mean 27 kg/m<sup>2</sup>,

Q4: mean 29 kg/m<sup>2</sup>, Q5: mean 34 kg/m<sup>2</sup>). Where height and/or weight measurements were missing participants were categorised into an 'unknown' group (0.6%).

## Smoking:

Current smoking status was derived from the touchscreen questionnaires at baseline 'Do you smoke tobacco now?' with the options 'Yes, on most or all days', 'Only occasionally', 'No' and 'Prefer not to answer' and 'In the past, how often have you smoked tobacco?' with the options 'Smoked on most or all days', 'Smoked occasionally', 'Just tried once or twice', 'I have never smoked', 'Prefer not to answer'. Number of cigarettes smoked per day was obtained from the question 'About how many cigarettes do you smoke on average each day?' apart from choosing a number, participants could answer, 'less than one', 'do not know' and 'prefer not to answer'. Using these two questions, smoking status was categorised into 5 groups 'never smoker', 'former smoker', 'current smoker <15 cigarettes/day', 'current smoker ≥15 cigarettes/day' and 'current smoker, amount unknown ' and 'unknown' smoking status (0.6%).

### Physical activity:

Physical activity was assessed using a list of questions within the baseline touchscreen questionnaire that were adapted from the short form International Physical activity questionnaire (IPAQ). The questionnaire was validated in adults across 12 countries [10]. The questionnaire assesses frequency, duration and of three types of activity walking, moderate and vigorous activity. In UK Biobank the question on duration was only asked if participants answered the question on frequency with a number other than zero. Physical activity data was cleaned according to the IPAQ protocol [11]. Excess metabolic equivalents (METs) were calculated by multiplying the sum of walking time per week with 2.3, moderate activity time per week with 3.0 and vigorous activity per week with 7.0 excess METs. Where a type of activity was missing but others were available this type was treated as zero METs of this activity. Excess METs include only additional activity above basal resting metabolic rates [12, 13]. Physical activity was then categorised into 3 groups (high, moderate, low) using cut-off of over 50 excess MET per week, between 10 and 50 excess METs per week and less than 10 excess MET per week. These cut-off have been used by Perez-Cornago et al. [14]. Participants with missing information and participants who reported they were unable to walk were grouped in an 'unknown' group (4.0%).

#### Alcohol intake:

Alcohol intake was assessed with 6 questions covering *monthly* intake of red wine 'In an average month, how many glasses of red wine would you drink? (There are six glasses in an average bottle)', white wine or champagne 'In an average month, how many glasses of white wine or champagne would you drink? (There are six glasses in an average bottle)', beer plus cider 'In an average month, how many pints of beer or cider would you drink? (Include bitter, lager, stout, ale, Guinness)', spirits 'In an average month, how many measures of spirits or liqueurs would you drink? (there are 25 standard measures in a normal sized bottle; spirits include drinks such as whisky, gin, rum, vodka, brandy)', and fortified wine 'In an average month, how many glasses of fortifies wine would you drink? (There are 12 glasses in an average bottle) (Fortified wines include drinks such as sherry, port,

vermouth)'; 6 questions covering *weekly* intake of the above types of alcoholic beverages, and one questions on overall alcohol intake frequency 'About how often do you drink alcohol?' which included a scale of 'Daily or almost daily', 'Three or four times a week', 'Once or twice a week', 'One to three times a month', 'Special occasions only', 'Never' and 'Prefer not to answer'. Red wine, white wine, spirits and fortified wines were assigned an average of 10 g alcohol per serving, beer and cider 20g alcohol per serving. Total drinking per day was calculated from total alcohol intake per week and month, where weekly intakes were unavailable. Total drinking was categories into 4 groups: 'non-drinker', '<1 g/day', '1-<10 g/day', '10-<20 g/day', '≥20 g/day' and 'unknown' (0.7%). Participants reporting their overall drinking frequency as drinking only at special occasions were added to the group of those drinking less than 1g/day and those reporting never drinking alcohol were categorised as never-drinkers.

## Total fruit and vegetable intake:

Fruit and vegetable intake was based on touchscreen questions regarding cooked vegetables 'On average how many heaped tablespoons of cooked vegetables would you eat per day? (Do not include potatoes; put '0' if you do not eat any)', raw vegetables 'On average how many heaped tablespoons of salad or raw vegetables would you eat per day? (Include lettuce, tomato in sandwiches; put '0' if you do not eat any)', questions included a depiction of what a heaped tablespoon of these types of vegetables would look like on an average sized plate, and fresh fruit 'About how many pieces of fresh fruit would you eat per day? (Count one apple, one banana, 10 grapes etc. as one piece; put `0' if you do not eat any)'. We considered one serving of either fruit or vegetables as one piece of fruit and two heaped tablespoon of vegetables, respectively. The sum of servings of either fruit or vegetables was categorised as '≤3 servings/day', '3-<4 servings/day', '4-<6 servings/day', '≥6 servings/day' and 'unknown' (2.3%).

## Estimated cereal fibre intake:

Fibre intake from bread and cereal was estimated based on a method used by Bradbury at al. in the same dataset, and all details can be found in the original publication [5]. Briefly, fibre intake was calculated by multiplying frequency of intakes with fibre content of the type of bread and cereal reported being mainly eaten. Frequency of bread and cereal intake was based on the questions 'How many slices of bread do you eat each week' and 'How many bowls of cereal do you eat a week?' with an open ended answer, and additional options less than one, do not know or prefer not to answer. If these questions were answered with one or more times a second question was asked ('What type of bread', 'Do not know' and 'Prefer not to answer' and respectively 'What type of cereal do you mainly eat?' with possible answers 'Bran cereal (e.g. All Bran, Branflakes)', 'Biscuit cereal (e.g. Weetabix)', 'Oat cereal (e.g. Ready Brek, porridge)', 'Muesli/ Other (e.g. Cornflakes, Frosties)', 'Do not know' and 'Prefer not to answer '. Estimated fibre intake from bread and breakfast cereal was categorised into sex-specific quintiles (Women: Q1: mean 1.05 g/day, Q2: mean 2.47 g/day, Q3: mean 3.73 g/day Q4: mean 5.28 g/day, Q5: mean 8.42 g/day; Men: Q1: mean 1.30 g/day, Q2: mean

2.81 g/day, Q3: mean 4.31 g/day, Q4: mean 6.18 g/day, Q5: mean 9.85 g/day). Participants who did not report intake of bread and cereals or preferred not to answer were grouped as 'unknown' (2.4%).

## Menopausal status:

Menopausal status was assessed using the question 'Have you had your menopause (periods stopped)?'. For participants who answered this question with 'not sure had hysterectomy', 'not sure other reason' or 'prefer not to answer' information on bilateral oophorectomy, use of HRT and age at recruitment were used to categorise participants. Participants were categorised postmenopausal if they (1) reported having their menopause ('Have you had your menopause (periods stopped)?'), (2) were over the age of 53, (3) reported a bilateral oophorectomy ('Have you had both ovaries removed?') or (4) reported Hormone replacement therapy (HRT) use. Participants were categorised 'premenopausal' if they reported: (1) not having their menopause, (2) were younger than 45 and (3) did not report a bilateral oophorectomy. Participants were regrouped to 'menopause' if they reported to not have their menopause but were over the age of 55 at recruitment and regrouped into an 'unknown' category if they reported not having had their menopause but having had a bilateral oophorectomy or having used HRT. Participants with missing information on menopausal status and who could not be reassigned using the additional information as described above were also grouped into the 'unknown' category (5.7%).

## Parity:

Parity was assessed with the question 'How many children have you given birth to? (Please include live births only)' in the baseline touchscreen questionnaire. We categorised parity into 'nulliparous', 'one to two', 'three or more'. Participants, who did not answer this question or answered 'Prefer not to answer', were grouped in an 'unknown' category (0.3%).

## HRT:

Use of HRT was assessed using three questions to assign the categories 'never', 'past', 'current', and 'unknown'. Never was assigned to those who replied 'no' to the question 'Have you ever used hormone replacement therapy (HRT)?' those who answered 'do not know', 'prefer not to answer' or who were missing an answer to this question were grouped 'unknown' (0.6%). Current and former intake was assessed comparing age at recruitment with answers to the questions 'How old were you when you last used HRT?' and 'How old were you when you first used HRT' that were asked after they had indicated that they had used HRT.

## Oral contraceptive pill (OCP):

OCP intake was assessed using three questions to assign the categories 'never', 'past', 'current', and 'unknown'. Never was assigned to those who replied 'no' to the question 'Have you ever taken the contraceptive pill? (include the 'mini pill')', those replied 'do not know', 'prefer not to answer' or who were missing an answer were grouped 'unknown' (0.5%). Current and former intake was assessed comparing age at recruitment with answers to the questions 'How old were you when you last used the contraceptive pill?' and 'How old were you when you first went on the contraceptive pill' that were asked after they had indicated that they had used the contraceptive pill.

## Skin colour:

Skin colour was assessed with the question 'What best describes your skin without tanning?'. We categorised answers into 'very fair', 'fair', 'light olive', 'dark olive', 'brown/black'. Participants, who did not answer this question, reported 'Do not know' or 'Prefer not to answer' were grouped in an 'unknown' category (1.6%).

## Hair colour:

Hair colour was assessed with the question 'What best describes your natural hair colour? (If your hair colour is grey, the colour before you went grey)'. Answers were categorised into 'blonde', 'red', 'light brown' 'dark brown' and 'black'. Participants, who did not answer this question, reported 'other', 'Do not know' or 'Prefer not to answer' were grouped in an 'unknown' category (1.7%).

## Skin reaction to sun exposure:

Skin reaction to sun exposure was assessed with the question 'What would happen to your skin if it was repeatedly exposed to bright sunlight without any protection'. Answers were categorised into 'get very tanned', 'get moderately tanned', 'get mildly or occasionally tanned' and 'never tan, only burn'. Participants, who did not answer this question, reported 'Do not know' or 'Prefer not to answer' were grouped in an 'unknown' category (3.7%).

## Sun or UV protection use:

Use of sun or UV protection was assessed with the question 'Do you wear sun protection (e.g. sunscreen lotion, hat) when you spend time outdoors in the summer?'. Answers were categorised into 'never/rarely', 'sometime', 'most of the time', 'always' and 'do not go out in sunshine'. Participants, who did not answer this question, reported 'Do not know' or 'Prefer not to answer' were grouped in an 'unknown' category (1.2%).

## Sunburns before age 15:

History of childhood sunburn was identified with the question 'Before the age of 15, how many times did you suffer sunburn that was painful for at least 2 days or caused blistering'. We dichotomised answers to never versus ever. Participants, who did not answer this question, answered 'Do not know' or 'Prefer not to answer' were grouped in an 'unknown' category (25.1%).

## Solarium use:

Solarium use was assessed with the question 'How many times a year would you use a solarium or sunlamp?'. We categorised answers into 'never', '>0-2 times a year' and '≥3 times a year'. Participants, who did not answer this question, reported 'Do not know' or 'Prefer not to answer' were grouped in an 'unknown' category (2.1%).

## **References**

1. UK Biobank Coordinating Centre. Ammendum to Main Study Protocol: Category 1 enhanced phenotyping at baseline assessment visit in last 200,000 participants and subsequent invitation to complete web-based diet questionnaire. Stockport: UK Biobank Coordinating Centre; 2009.

2. Greenwood DC, Hardie LJ, Frost GS, Alwan NA, Bradbury KE, Carter M, et al. Validation of the Oxford WebQ Online 24-hour Dietary Questionnaire Using Biomarkers. American Journal of Epidemiology. 2019. <u>https://doi.org/10.1093/aje/kwz165</u>. PMID: 31318012.

3. Galante J, Adamska L, Young A, Young H, Littlejohns TJ, Gallacher J, et al. The acceptability of repeat Internet-based hybrid diet assessment of previous 24-h dietary intake: administration of the Oxford WebQ in UK Biobank. Br J Nutr. 2015;115(4):681-6. Epub 12/11. https://doi.org/10.1017/S0007114515004821. PMID: 26652593.

Willett W. Nutritional epidemiology. 3rd ed. Oxford: Oxford University Press; 2013.

 Bradbury KE, Young HJ, Guo W, Key TJ. Dietary assessment in UK Biobank: an evaluation of the performance of the touchscreen dietary questionnaire. J Nutr Sci. 2018;7:e6. Epub 02/01. https://doi.org/10.1017/jns.2017.66. PMID: 29430297.

6. Key TJ, Balkwill A, Bradbury KE, Reeves GK, Kuan AS, Simpson RF, et al. Foods, macronutrients and breast cancer risk in postmenopausal women: a large UK cohort. Int J Epidemiol. 2018:dyy238-dyy. <u>https://doi.org/10.1093/ije/dyy238</u>. PMID: 30412247.

7. Clarke R, Shipley M, Lewington S, Youngman L, Collins R, Marmot M, et al. Underestimation of risk associations due to regression dilution in long-term follow-up of prospective studies. Am J Epidemiol. 1999;150(4):341-53. Epub 1999/08/24.

https://doi.org/10.1093/oxfordjournals.aje.a010013. PMID: 10453810.

8. University of East Anglia SoES, University of Manchester, Cathie Marsh Centre for Census and Survey Research, University of Manchester, MIMAS, Census Dissemination Unit (CDU). Deprivation Scores Based on 1991 and 2001 Census Area Statistics. [data collection]. 2nd Edition. SN: 5850, 2013.

9. Townsend P, Phillimore P, Beattie A. Health and deprivation: inequality and the north. London: Routledge; 1989.

10. Craig CL, Marshall AL, Sjöström M, Bauman AE, Booth ML, Ainsworth BE, et al. International Physical Activity Questionnaire: 12-Country reliability and validity. Medicine and science in sports and exercise. 2003;35(8):1381-95. <u>https://doi.org/10.1249/01.MSS.0000078924.61453.FB</u>. PMID: 12900694.

11. IPAQ. Guidelined for Data Processing and Analysis of the International Physical activity Questionnaire (IPAQ) - Short and Long Forms 2005 [cited 2018 30/10/2018]. Available from: <u>https://docs.google.com/viewer?a=v&pid=sites&srcid=ZGVmYXVsdGRvbWFpbnx0aGVpcGFxfGd4Oj</u> <u>E0NDgxMDk3NDU1YWRIZTM</u>.

12. Armstrong MEG, Cairns BJ, Green J, Reeves GK, Beral V, The Million Women Study Collaborators. Reported frequency of physical activity in a large epidemiological study: relationship to specific activities and repeatability over time. BMC Med Res Methodol. 2011;11(1):97. https://doi.org/10.1186/1471-2288-11-97. PMID: 21831330.

13. Howley ET. Type of activity: resistance, aerobic and leisure versus occupational physical activity. Medicine and science in sports and exercise. 2001;33(6 Suppl):S364-9; discussion S419-20. Epub 28/06/2001. PMID: 11427761.

14. Perez-Cornago A, Key TJ, Allen NE, Fensom GK, Bradbury KE, Martin RM, et al. Prospective investigation of risk factors for prostate cancer in the UK Biobank cohort study. Br J Cancer. 2017;117:1562. <u>https://doi.org/10.1038/bjc.2017.312</u>. PMID: 28910820.

## Supplementary Tables

Meat intake	g/day*	All participants (n = 475,023)	Participants who developed any incident cancer (n = 28,955)
Total meat, n (%)			• • •
<3 times/week	33.7	57,969 (12.2)	3,006 (10.4)
3-<5 times/week	84.7	119,282 (25.1)	7,517 (26.0)
5-<7 times/week	99.2	153,688 (32.4)	9,417 (32.5)
≥7 times/week	116.2	136,481 (28.7)	8,539 (29.5)
Unknown		7,603 (1.6)	476 (1.6)
Red & processed meat, n (%	5)		· · · ·
≤1 times/week	10.5	44,027 (9.3)	2,090 (7.2)
>1-<3 times/week	48.7	160,080 (33.7)	9,460 (32.7)
3-<5 times/week	65.0	140,683 (29.6)	8,849 (30.6)
≥5 times/week	79.3	122,987 (25.9)	8,105 (28.0)
Unknown		7,246 (1.5)	451 (1.6)
Red meat, n (%)			
<1 times/week	6.5	47,725 (10.0)	2,310 (8.0)
1-<2 times/week	32.6	184,629 (38.9)	10,809 (37.3)
2-<4 times/week	45.1	173,889 (36.6)	11,338 (39.2)
≥4 times/week	55.1	62,121 (13.1)	4,088 (14.1)
Unknown		6,659 (1.4)	410 (1.4)
Processed meat, n (%)			
0 times/week	4.1	44,046 (9.3)	2,194 (7.6)
>0-<1 times/week	15.6	143,524 (30.2)	8,529 (29.5)
1-<2 times/week	21.3	138,083 (29.1)	8,708 (30.1)
≥2 times/week	29.1	147,228 (31.0)	9,406 (32.5)
Unknown		2,142 (0.5)	118 (0.4)
Poultry, n (%)			
<1 times/week	12.2	75,015 (15.8)	4,597 (15.9)
1-<2 times/week	27.4	169,479 (35.7)	11,027 (38.1)
≥2 times/week	39.4	228,554 (48.1)	13,230 (45.7)
Unknown		1,975 (0.4)	101 (0.3)

## S1 Table. Baseline distribution of meat intake of included UK Biobank participants

\*Mean intakes are based on participants with re-measured 24-h dietary recall based on the WebQ.

# S2 Table. Baseline characteristics by red and processed meat intake

	Red and processed meat intake (times/week), (mean g/day*)					
Characteristics†	≤1 (10.5) >1-<3 (48.7) 3-<5 (65.0) ≥5 (79.3)					
Sociodemographic						
Sex, n (%)						
Women	31,323 (71.1)	101,755 (63.6)	71,684 (51.0)	47,660 (38.8)		
Men	12,704 (28.9)	58,325 (36.4)	68,999 (49.0)	75,327 (61.2)		
Age (years)	54.9 (8.2)	56.5 (8.0)	56.4 (8.1)	56.5 (8.2)		
Ethnicity, n (%)		( )		( )		
White	38,458 (87.4)	151,738 (94.8)	134,518 (95.6)	116,823 (95.0)		
Asian or Asian British	3,468 (7.9)	2,914 (1.8)	2,245 (1.6)	1,897 (1.5)		
Black or Black British	886 (2.0)	2,607 (1.6)	1,685 (1.2)	2,047 (1.7)		
Mixed Race or other	998 (2.3)	2,323 (1.5)	1,807 (1.3)	1,774 (1.4)		
Unknown	217 (0.5)	498 (0.3)	428 (0.3)	446 (0.4)		
Townsend deprivation, n (%)	211 (0.0)	100 (0.0)	120 (0.0)	110 (011)		
Most affluent (mean -4.7)	7,038 (16.0)	32,848 (20.5)	29,803 (21.2)	24,668 (20.1)		
2 (mean -3.3)	7,547 (17.1)	32,869 (20.5)	29,202 (20.8)	24,403 (19.8)		
3 (mean -2.1)	8,355 (19.0)	32,757 (20.5)	28,326 (20.1)	24,346 (19.8)		
4 (mean -0.9)	10,138 (23.0)	31,701 (19.8)	27,420 (19.5)	24,043 (19.5)		
Most deprived (mean 3.8)	10,887 (24.7)	29,690 (18.5)	25,779 (18.3)	25,375 (20.6)		
Unknown		,				
	62 (0.1)	215 (0.1)	153 (0.1)	152 (0.1)		
Qualification, n (%)						
College or university degree/vocational qualification	28,497 (64.7)	96,080 (60.0)	82,369 (58.5)	72,442 (58.9)		
National examination at ages 17-18	2,497 (64.7)	8,708 (5.4)	7,796 (5.5)	6,626 (5.4)		
National examination at age 16						
5	6,321 (14.4)	27,682 (17.3)	24,135 (17.2)	19,676 (16.0)		
Other/unknown	6,718 (15.3)	27,610 (17.2)	26,383 (18.8)	24,243 (19.7)		
Employment, n (%)			04 040 (50 0)	70 405 (57 0)		
In paid employment	27,657 (62.8)	93,973 (58.7)	81,649 (58.0)	70,105 (57.0)		
Pension	10,229 (23.2)	48,221 (30.1)	42,698 (30.4)	37,181 (30.2)		
Not in paid employment	5,557 (12.6)	16,487 (10.3)	15,237 (10.8)	14,565 (11.8)		
Unknown	584 (1.3)	1,399 (0.9)	1,099 (0.8)	1,136 (0.9)		
Living with a spouse/partner, n (%)						
Living with partner	27,161 (61.7)	112,484 (70.3)	107,081 (76.1)	93,472 (76.0)		
Not living with partner	16,570 (37.6)	46,937 (29.3)	33,192 (23.6)	29,125 (23.7)		
Unknown	296 (0.7)	659 (0.4)	410 (0.3)	390 (0.3)		
Anthropometric						
Standing height (cm) in women	162.5 (6.5)	162.6 (6.3)	162.5 (6.3)	162.3 (6.3)		
Standing height (cm) in men	175.3 (7.1)	175.7 (6.8)	175.8 (6.8)	175.7 (6.8)		
BMI (kg/m²), mean (SD)	25.9 (4.7)	27.1 (4.7)	27.6 (4.8)	28.1 (4.9)		
Lifestyle						
Smoking, n (%)						
None	26,348 (59.8)	90,453 (56.5)	76,690 (54.5)	62,691 (51.0)		
Former	13,967 (31.7)	54,802 (34.2)	48,536 (34.5)	43,272 (35.2)		
Current <15 cigarettes/day	1,297 (2.9)	4,581 (2.9)	4,247 (3.0)	4,074 (3.3)		
Current ≥15 cigarettes/day	1,030 (2.3)	4,825 (3.0)	6,014 (4.3)	7,623 (6.2)		
Current, amount unknown	1,214 (2.8)	4,876 (3.0)	4,727 (3.4)	4,914 (4.0)		
Unknown	171 (0.4)	543 (0.3)	469 (0.3)	413 (0.3)		
Physical activity level, n (%)	( )		( )			
High ≥50 excess METs	7,773 (17.7)	24,717 (15.4)	21,860 (15.5)	20,458 (16.6)		
Moderate 10-<50 excess METs	22,381 (50.8)	80,044 (50.0)	68,201 (48.5)	58,009 (47.2)		
Low <10 excess METs	12,408 (28.2)	49,712 (31.1)	45,471 (32.3)	39,711 (32.3)		
Unknown	1,465 (3.3)	5,607 (3.5)	5,151 (3.7)	4,809 (3.9)		
Alcohol intake, n (%)	.,	-,,	-,,	.,()		
None drinkers	7,506 (17.0)	11,941 (7.5)	9,611 (6.8)	7,793 (6.3)		
<1 g/day	6,814 (15.5)	19,867 (12.4)	14,470 (10.3)	10,863 (8.8)		
1-<10 g/day	14,744 (33.5)	57,217 (35.7)	43,230 (30.7)	31,589 (25.7)		
10-<20 g/day			43,230 (30.7) 31,683 (22.5)			
	7,987 (18.1)	36,198 (22.6)		25,627 (20.8)		
≥20 g/day	6,740 (15.3)	34,047 (21.3)	41,070 (29.2)	46,546 (37.8)		
Unknown	236 (0.5)	810 (0.5)	619 (0.4)	569 (0.5)		
Diet						
Fruit & vegetable intake (servings/day)	5.59 (3.19)	4.89 (2.54)	4.50 (2.45)	4.33 (2.50)		
Estimated cereal fibre intake (g/day)	4.66 (3.11)	4.52 (2.89)	4.52 (2.91)	4.44 (2.96)		
Women's health						

Menopausal status, n (%)		00.040 (00.0)	47.040 (00.0)	44,000 (00 5)
Premenopausal	8,962 (28.6)	22,948 (22.6)	17,040 (23.8)	11,209 (23.5)
Postmenopausal	20,589 (65.7)	73,273 (72.0)	50,663 (70.7)	33,726 (70.8)
	1,772 (5.7)	5,534 (5.4)	3,981 (5.6)	2,725 (5.7)
Parity, n (%)	0.040 (00.0)	40 704 (40 4)	44 740 (40 4)	7 000 (45 0)
0 births	8,318 (26.6)	19,784 (19.4)	11,740 (16.4)	7,299 (15.3)
1-2 births	16,232 (51.8)	58,208 (57.2)	42,078 (58.7)	27,656 (58.0)
≥3 births Unknown	6,717 (21.4)	23,672 (23.3)	17,812 (24.8)	12,655 (26.6)
	56 (0.2)	91 (0.1)	54 (0.1)	50 (0.1)
Hormone replacement therapy use, n (%) Never	21,441 (68.5)	61,916 (60.8)	44,011 (61.4)	28,978 (60.8)
Past	7,951 (25.4)	33,165 (32.6)	23,018 (32.1)	15,560 (32.6)
Current	1,773 (5.7)	6,379 (6.3)	4,429 (6.2)	2,897 (6.1)
Unknown	158 (0.5)	295 (0.3)	226 (0.3)	225 (0.5)
Oral contraceptive pill use, n (%)	100 (0.0)	233 (0.3)	220 (0.3)	220 (0.0)
Never	6,598 (21.1)	18,180 (17.9)	12,850 (17.9)	8,919 (18.7)
Past	23,877 (76.2)	81,535 (80.1)	57,270 (79.9)	37,643 (79.0)
Current	691 (2.2)	1,813 (1.8)	1,388 (1.9)	918 (1.9)
Unknown	157 (0.5)	227 (0.2)	176 (0.2)	180 (0.4)
Men's health	107 (0.0)	221 (0.2)	110 (0.2)	100 (0.1)
Enlarged prostate, n (%)				
No/unknown	43,635 (99.1)	157,984 (98.7)	138,441 (98.4)	120,712 (98.2)
Yes	392 (0.9)	2,096 (1.3)	2,242 (1.6)	2,275 (1.8)
Skin cancer related factors		_,,	_, ()	_, ()
Skin colour, n (%)				
Very fair	4,024 (9.1)	12,051 (7.5)	10,257 (7.3)	9,329 (7.6)
Fair	26,991 (61.3)	106,840 (66.7)	96,058 (68.3)	83,968 (68.3)
Light olive	8,145 (18.5)	30,901 (19.3)	25,896 (18.4)	21,300 (17.3)
Dark olive	796 (1.8)	2,836 (1.8)	2,612 (1.9)	2,418 (2.0)
Brown/black	3,450 (7.8)	5,449 (3.4)	4,014 (2.9)	4,157 (3.4)
Unknown	621 (1.4)	2,003 (1.3)	1,846 (1.3)	1,815 (1.5)
Hair colour, n (%)				
Blonde	4,223 (9.6)	17,299 (10.8)	14,933 (10.6)	12,947 (10.5)
Red	1,977 (4.5)	7,011 (4.4)	5,902 (4.2)	5,056 (4.1)
Light brown	15,605 (35.4)	62,217 (38.9)	54,767 (38.9)	47,003 (38.2)
Dark brown	16,815 (38.2)	59,983 (37.5)	52,499 (37.3)	45,152 (36.7)
Black	4,886 (11.1)	11,538 (7.2)	10,568 (7.5)	10,929 (8.9)
Other/unknown	521 (1.2)	2,032 (1.3)	2,014 (1.4)	1,900 (1.5)
Skin reaction, n (%)				
Get very tanned	8,779 (19.9)	32,382 (20.2)	29,384 (20.9)	27,429 (22.3)
Moderately tanning	15,901 (36.1)	62,216 (38.9)	54,898 (39.0)	47,573 (38.7)
Mildly/occasionally tanning	9,683 (22.0)	33,705 (21.1)	28,998 (20.6)	23,713 (19.3)
Never tanning, only burning	7,658 (17.4)	26,683 (16.7)	23,002 (16.4)	20,158 (16.4)
Unknown	2,006 (4.6)	5,094 (3.2)	4,401 (3.1)	4,114 (3.3)
UV protection use, n (%)				
Never/rarely, n (%)	5,220 (11.9)	12,695 (7.9)	13,447 (9.6)	15,808 (12.9)
Sometimes	12,597 (28.6)	49,434 (30.9)	47,891 (34.0)	44,839 (36.5)
Most of the time	14,717 (33.4)	58,318 (36.4)	50,347 (35.8)	40,856 (33.2)
Always	10,459 (23.8)	37,399 (23.4)	27,087 (19.3)	19,655 (16.0)
Do not go out in the sunshine	511 (1.2)	851 (0.5)	681 (0.5)	694 (0.6)
Unknown	523 (1.2)	1,383 (0.9)	1,230 (0.9)	1,135 (0.9)
Solarium use, n (%)				
	39,008 (88.6)	142,438 (89.0)	125,412 (89.1)	109,209 (88.8)
>0-2 times/year	2,258 (5.1)	8,993 (5.6)	7,951 (5.7)	7,378 (6.0)
≥3 times/year	1,619 (3.7)	6,124 (3.8)	5,017 (3.6)	4,198 (3.4)
Unknown	1,142 (2.6)	2,525 (1.6)	2,303 (1.6)	2,202 (1.8)
Childhood sunburn, n (%)	10 222 (42 0)	67 049 (44 0)	56 575 (10 2)	17 575 (20 6)
Never Ever	19,333 (43.9)	67,048 (41.9)	56,575 (40.2)	47,525 (38.6)
	14,564 (33.1) 10,130 (23.0)	53,785 (33.6) 39 247 (24 5)	48,804 (34.7) 35 304 (25 1)	44,470 (36.2)
Unknown	10,130 (23.0)	39,247 (24.5)	35,304 (25.1)	30,992 (25.2)
Meat intake*				
Total meat, n (%)				
<3 times/week (mean 33.7 g/day)	33,507 (76.1)	24,462 (15.3)	0 (0.0)	0 (0.0)
	, , , ,			× /

3-<5 times/week (mean 84.7 g/day)	9,413 (21.4)	71,012 (44.4)	38,857 (27.6)	0 (0.0)
5-<7 times/week (mean 99.2 g/day)	905 (2.1)	61,070 (38.1)	64,865 (46.1)	26,848 (21.8)
≥7 times/week (mean 116.2 g/day)	144 (0.3)	3,426 (2.1)	36,865 (26.2)	96,046 (78.1)
Unknown, n(%)	58 (0.1)	110 (0.1)	96 (0.1)	93 (0.1)
Red meat, n (%)		· · ·	. ,	
<1 times/week (mean 6.5 g/day)	39,848 (90.5)	3,414 (2.1)	3,719 (2.6)	639 (0.5)
1-<2 times/week (mean 32.6 g/day)	4,179 (9.5)	128,320 (80.2)	45,920 (32.6)	5,991 (4.9)
2-<4 times/week (mean 45.1 g/day)	0 (0.0)	28,346 (17.7)	83,920 (59.7)	61,458 (50.0)
≥4 times/week (mean 55.1 g/day)	0 (0.0)	0 (0.0)	7,124 (5.1)	54,899 (44.6)
Processed meat, n (%)				
0 times/week (mean 4.1 g/day)	31,724 (72.1)	8,781 (5.5)	2,543 (1.8)	686 (0.6)
>0- <1 times/week (mean 15.6 g/day)	10,548 (24.0)	94,759 (59.2)	28,538 (20.3)	8,397 (6.8)
1-<2 times/week (mean 21.3 g/day)	1,755 (4.0)	56,540 (35.3)	59,963 (42.6)	18,212 (14.8)
≥2 times/week (mean 29.1 g/day)	0 (0.0)	0 (0.0)	49,639 (35.3)	95,692 (77.8)
Poultry, n (%)				
<1 times/week (mean 12.2 g/day)	26,366 (59.9)	23,492 (14.7)	13,479 (9.6)	10,760 (8.7)
1-<2 times/week (mean 27.4 g/day)	7,141 (16.2)	61,116 (38.2)	56,697 (40.3)	42,295 (34.4)
≥2 times/week (mean 39.4 g/day)	10,462 (23.8)	75,362 (47.1)	70,411 (50.0)	69,839 (56.8)
Unknown	58 (0.1)	110 (0.1)	96 (0.1)	93 (0.1)

BMI, Body mass index; MET, metabolic equivalents.

\*Mean intakes are based on participants with re-measured 24-h dietary recall based on the WebQ.

†Mean (Standard deviation) unless otherwise specified.

# S3 Table. Baseline characteristics by poultry intake

	Poultry intake (times/week), (mean g/day*)				
Characteristics†	≤1 (12.2)	>1- <3 (27.4)	3-<5 (39.4)		
Sociodemographic					
Sex, n (%)					
Women	41,883 (55.8)	88,925 (52.5)	124,256 (54.4)		
Men	33,132 (44.2)	80,554 (47.5)	104,298 (45.6)		
Age (years)	56.6 (8.1)	57.2 (7.9)	55.5 (8.1)		
Ethnicity, n (%)					
White	69,358 (92.5)	161,955 (95.6)	214,134 (93.7)		
Asian or Asian British	3,216 (4.3)	3,004 (1.8)	4,822 (2.1)		
Black or Black British	903 (1.2)	1,872 (1.1)	4,937 (2.2)		
Mixed Race or other	1,162 (1.5)	2,108 (1.2)	3,913 (1.7)		
Unknown	376 (0.5)	540 (0.3)	748 (0.3)		
Fownsend deprivation, n (%)	570 (0.5)	540 (0.5)	740 (0.3)		
Most affluent (mean -4.7)	11,932 (15.9)	25 291 (20 9)	47 662 (20.0)		
2 (mean -3.3)		35,281 (20.8)	47,662 (20.9)		
3 (mean -2.1)	13,076 (17.4)	34,755 (20.5)	46,802 (20.5)		
4 (mean -0.9)	14,561 (19.4)	34,075 (20.1)	45,932 (20.1)		
	16,861 (22.5)	33,073 (19.5)	44,536 (19.5)		
Most deprived (mean 3.8) Unknown	18,499 (24.7)	32,125 (19.0)	43,287 (18.9)		
	86 (0.1)	170 (0.1)	335 (0.1)		
Qualification, n (%)					
College or university degree/vocational	40.754 (00.0)	00.040 (50.0)	400 400 (50 0)		
qualification	46,754 (62.3)	98,313 (58.0)	136,126 (59.6)		
National examination at ages 17-18	3,846 (5.1)	8,752 (5.2)	13,188 (5.8)		
National examination at age 16	10,302 (13.7)	27,992 (16.5)	40,291 (17.6)		
Other/unknown	14,113 (18.8)	34,422 (20.3)	38,949 (17.0)		
Employment, n (%)					
In paid employment	42,596 (56.8)	93,622 (55.2)	139,540 (61.1)		
Pension	21,967 (29.3)	55,867 (33.0)	62,017 (27.1)		
Not in paid employment	9,566 (12.8)	18,410 (10.9)	24,993 (10.9)		
Unknown	886 (1.2)	1,580 (0.9)	2,004 (0.9)		
Living with a spouse/partner, n (%)					
Living with partner	46,848 (62.5)	125,387 (74.0)	171,042 (74.8)		
Not living with partner	27,739 (37.0)	43,436 (25.6)	56,709 (24.8)		
Unknown	428 (0.6)	656 (0.4)	803 (0.4)		
Anthropometric					
Standing height (cm) in women	162.6 (6.5)	162.4 (6.3)	162.4 (6.3)		
Standing height (cm) in men	175.4 (7.0)	175.6 (6.9)	175.8 (6.8)		
BMI (kg/m²)	26.6 (4.8)	27.3 (4.6)	27.8 (4.9)		
Lifestyle					
Smoking, n (%)					
None	39,774 (53.0)	91,572 (54.0)	127,694 (55.9)		
Former	25,820 (34.4)	58,462 (34.5)	77,747 (34.0)		
Current <15 cigarettes/day	2,585 (3.4)	5,268 (3.1)	6,576 (2.9)		
Current ≥15 cigarettes/day	3,713 (4.9)	7,630 (4.5)	8,500 (3.7)		
Current, amount unknown	2,808 (3.7)	5,880 (3.5)	7,278 (3.2)		
Unknown	315 (0.4)	667 (0.4)	759 (0.3)		
Physical activity level, n (%)			100 (0.0)		
High $\geq$ 50 excess METs	12,018 (16.0)	26,068 (15.4)	37,328 (16.3)		
Moderate 10-<50 excess METs	36,618 (48.8)	82,371 (48.6)	111,398 (48.7)		
Low <10 excess METs	23,401 (31.2)	54,433 (32.1)	71,420 (31.2)		
Unknown	2,978 (4.0)	6,607 (3.9)	8,408 (3.7)		
Alcohol intake, n (%)	2,910 (4.0)	0,007 (3.9)	0,400 (3.7)		
	0.056 (44.0)	10.004 (7.4)	10 040 (7 A)		
None drinkers	8,856 (11.8)	12,094 (7.1)	16,943 (7.4)		
<1 g/day	10,017 (13.4)	18,203 (10.7)	24,812 (10.9)		
1-<10 g/day	23,631 (31.5)	53,600 (31.6)	70,979 (31.1)		
10-<20 g/day	14,675 (19.6)	37,461 (22.1)	50,047 (21.9)		
≥20 g/day	17,364 (23.1)	47,270 (27.9)	64,681 (28.3)		

Unknown	472 (0.6)	851 (0.5)	1,092 (0.5)
Diet			
Fruit & vegetable intake (servings/day)	4.83 (2.97)	4.50 (2.43)	4.78 (2.60)
Estimated cereal fibre intake (g/day)	4.64 (3.10)	4.51 (2.91)	4.46 (2.90)
Women's health			
Menopausal status, n (%)			
Premenopausal	10,061 (24.0)	18,217 (20.5)	32,444 (26.1)
Postmenopausal	29,715 (70.9)	66,399 (74.7)	84,033 (67.6)
Unknown	2,107 (5.0)	4,309 (4.8)	7,779 (6.3)
Parity, n (%)			
0 births	11,590 (27.7)	16,043 (18.0)	19,914 (16.0)
1-2 births	21,256 (50.8)	51,261 (57.6)	72,995 (58.7)
≥3 births	8,971 (21.4)	21,529 (24.2)	31,236 (25.1)
Unknown	66 (0.2)	92 (0.1)	111 (0.1)
Hormone replacement therapy use, n (%)			
Never	27,203 (64.9)	53,290 (59.9)	77,474 (62.4)
Past	12,072 (28.8)	29,959 (33.7)	38,493 (31.0)
Current	2,400 (5.7)	5,362 (6.0)	7,835 (6.3)
Unknown	208 (0.5)	314 (0.4)	454 (0.4)
Oral contraceptive pill use, n (%)			
Never	8,873 (21.2)	17,361 (19.5)	21,154 (17.0)
Past	32,008 (76.4)	69,798 (78.5)	100,203 (80.6)
Current	791 (1.9)	1,535 (1.7)	2,522 (2.0)
Unknown	211 (0.5)	231 (0.3)	377 (0.3)
Men's health			
Enlarged prostate, n (%)			
No/unknown	73,846 (98.4)	166,698 (98.4)	225,443 (98.6)
Yes	1,169 (1.6)	2,781 (1.6)	3,111 (1.4)
Skin cancer related factors			
Skin colour, n (%)			
Very fair	6,377 (8.5)	12,392 (7.3)	17,251 (7.5)
Fair	49,904 (66.5)	115,766 (68.3)	150,980 (66.1)
Light olive	12,671 (16.9)	30,887 (18.2)	43,342 (19.0)
Dark olive	1,257 (1.7)	3,040 (1.8)	4,486 (2.0)
Brown/black	3,474 (4.6)	4,959 (2.9)	9,567 (4.2)
	1,332 (1.8)	2,435 (1.4)	2,928 (1.3)
Hair colour, n (%)			
Blonde	7,507 (10.0)	17,959 (10.6)	24,406 (10.7)
Red	3,246 (4.3)	7,158 (4.2)	9,702 (4.2)
Light brown	28,120 (37.5)	66,247 (39.1)	86,705 (37.9)
Dark brown	28,047 (37.4)	62,722 (37.0)	85,216 (37.3)
Black	6,869 (9.2)	12,802 (7.6)	19,573 (8.6)
Other/unknown Skin reaction, n (%)	1,226 (1.6)	2,591 (1.5)	2,952 (1.3)
Get very tanned	4F 400 (00 C)		40 404 (04 4)
Moderately tanning	15,488 (20.6)	35,425 (20.9)	48,121 (21.1)
Mildly/occasionally tanning	28,135 (37.5)	66,483 (39.2) 24,276 (20.2)	87,512 (38.3)
Never tanning, only burning	15,314 (20.4)	34,276 (20.2)	47,381 (20.7)
Unknown	12,980 (17.3)	27,865 (16.4)	37,542 (16.4)
UV protection use, n (%)	3,098 (4.1)	5,430 (3.2)	7,998 (3.5)
Never/rarely	10.276 (12.7)	16,789 (9.9)	21 257 (0.2)
Sometimes	10,276 (13.7)		21,257 (9.3)
Most of the time	25,608 (34.1) 24,025 (32.0)	58,323 (34.4) 58,850 (34.7)	72,617 (31.8) 82,489 (36.1)
Always	24,025 (32.0) 13,649 (18.2)	58,850 (34.7) 33,127 (19.5)	82,489 (36.1) 48,700 (21.3)
Do not go out in the sunshine			
Unknown	740 (1.0) 717 (1.0)	934 (0.6) 1 456 (0.9)	1,145 (0.5) 2 346 (1 0)
Solarium use, n (%)	717 (1.0)	1,456 (0.9)	2,346 (1.0)
Never	67 692 (00 2)	151 062 (20 7)	200 615 (07 0)
>0-2 times/year	67,682 (90.2) 3,918 (5.2)	151,963 (89.7) 9,402 (5.5)	200,645 (87.8) 13,516 (5.9)
	0,010 (0.2)	J, TUZ (J.J)	10,010 (0.8)

≥3 times/year	1,902 (2.5)	5,202 (3.1)	9,975 (4.4)
Unknown	1,513 (2.0)	2,912 (1.7)	4,418 (1.9)
Childhood sunburn, n (%)			, , ,
Never	30,661 (40.9)	69,542 (41.0)	92,589 (40.5)
Ever	25,186 (33.6)	56,949 (33.6)	80,350 (35.2)
Unknown	19,168 (25.6)	42,988 (25.4)	55,615 (24.3)
Meat and fish intake*			
Total meat, n (%)			
<3 times/week (mean 33.7 g/day)	42,706 (56.9)	15,263 (9.0)	0 (0.0)
3- <5 times/week (mean 84.7 g/day)	15,015 (20.0)	83,988 (49.6)	20,279 (8.9)
5- <7 times/week (mean 99.2 g/day)	11,134 (14.8)	47,033 (27.8)	95,521 (41.8)
≥7 times/week (mean 116.2 g/day)	5,242 (7.0)	20,965 (12.4)	110,274 (48.2)
Unknown	918 (1.2)	2,230 (1.3)	2,480 (1.1)
Red & processed meat, n (%)			
≤1 times/week (mean 10.5 g/day)	26,366 (35.1)	7,141 (4.2)	10,462 (4.6)
>1-<3 times/week (mean 48.7 g/day)	23,492 (31.3)	61,116 (36.1)	75,362 (33.0)
3-<5 times/week (mean 65.0 g/day)	13,479 (18.0)	56,697 (33.5)	70,411 (30.8)
≥5 times/week (mean 79.3 g/day)	10,760 (14.3)	42,295 (25.0)	69,839 (30.6)
Unknown	918 (1.2)	2,230 (1.3)	2,480 (1.1)
Red meat, n (%)			
<1 times/week (mean 6.5 g/day)	26,997 (36.0)	8,114 (4.8)	12,519 (5.5)
1-<2 times/week (mean 32.6 g/day)	28,816 (38.4)	67,611 (39.9)	88,055 (38.5)
2-<4 times/week (mean 45.1 g/day)	12,790 (17.0)	72,910 (43.0)	88,075 (38.5)
≥4 times/week (mean 55.1 g/day)	5,617 (7.5)	18,818 (11.1)	37,632 (16.5)
Unknown	795 (1.1)	2,026 (1.2)	2,273 (1.0)
Processed meat, n (%)			
0 times/week (mean 4.1 g/day)	24,785 (33.0)	7,763 (4.6)	11,432 (5.0)
>0-<1 times/week (mean 15.6 g/day)	21,752 (29.0)	54,282 (32.0)	67,332 (29.5)
1- <2 times/week (mean 21.3 g/day)	12,658 (16.9)	55,749 (32.9)	69,462 (30.4)
≥2 times/week (mean 29.1 g/day)	15,652 (20.9)	51,361 (30.3)	79,965 (35.0)
Unknown	168 (0.2)	324 (0.2)	363 (0.2)
BMI Body mass index: MET metabolic equival	ents		

BMI, Body mass index; MET, metabolic equivalents.

\*Mean intakes are based on participants with re-measured 24-h dietary recall based on the WebQ.

†Mean (Standard deviation) unless otherwise specified.

	Total meat intake (times/week), (mean g/day)								
Site (ICD-10)	Model				0 ,,	per 100 g higher			
		<3 (33.7)	3-<5 (84.7)	5-<7 (99.2)	≥7 (116.2)	intake	Ptrend		
	Total n	57969	119282	153688	136481	467420			
Oral (C00-C14)	Cases	54	129	198	169	550			
	HR (95%-CI), Model 0	1.00 (Ref.)	1.05 (0.76, 1.44)	1.20 (0.89, 1.63)	1.07 (0.78, 1.45)	1.12 (0.78, 1.61)	0.5265		
	HR (95%-CI), Model 1	1.00 (Ref.)	1.05 (0.76, 1.45)	1.21 (0.89, 1.64)	0.99 (0.72, 1.35)	1.02 (0.71, 1.46)	0.9330		
	HR (95%-CI), Model 2	1.00 (Ref.)	1.08 (0.78, 1.49)	1.24 (0.91, 1.69)	1.02 (0.74, 1.41)	1.06 (0.74, 1.53)	0.7483		
Oesophagus (C15)	Cases	48	125	156	196	525			
	HR (95%-CI), Model 0	1.00 (Ref.)	1.01 (0.72, 1.41)	0.95 (0.69, 1.31)	1.26 (0.91, 1.73)	1.35 (0.91, 2.00)	0.1355		
	HR (95%-CI), Model 1	1.00 (Ref.)	1.01 (0.72, 1.42)	0.95 (0.68, 1.31)	1.18 (0.85, 1.64)	1.24 (0.84, 1.84)	0.2853		
	HR (95%-CI), Model 2	1.00 (Ref.)	0.99 (0.70, 1.38)	0.91 (0.65, 1.27)	1.12 (0.81, 1.56)	1.16 (0.78, 1.72)	0.4659		
Stomach (C16)	Cases	31	86	102	129	348			
	HR (95%-CI), Model 0	1.00 (Ref.)	1.06 (0.70, 1.61)	0.97 (0.65, 1.45)	1.31 (0.88, 1.95)	1.40 (0.86, 2.28)	0.1730		
	HR (95%-CI), Model 1	1.00 (Ref.)	1.09 (0.72, 1.65)	1.00 (0.66, 1.50)	1.30 (0.87, 1.95)	1.38 (0.85, 2.24)	0.1986		
	HR (95%-CI), Model 2	1.00 (Ref.)	1.07 (0.71, 1.62)	0.96 (0.64, 1.45)	1.25 (0.83, 1.87)	1.30 (0.80, 2.13)	0.2904		
Colorectum (C18-20)*	Cases	283	816	1076	1019	3194			
	HR (95%-CI), Model 0	1.00 (Ref.)	1.21 (1.06, 1.39)	1.26 (1.10, 1.43)	1.35 (1.18, 1.54)	1.42 (1.22, 1.67)	<0.0001		
	HR (95%-CI), Model 1	1.00 (Ref.)	1.17 (1.02, 1.35)	1.21 (1.06, 1.38)	1.27 (1.11, 1.46)	1.33 (1.14, 1.56)	0.0004		
	HR (95%-CI), Model 2	1.00 (Ref.)	1.16 (1.01, 1.33)	1.18 (1.03, 1.35)	1.24 (1.08, 1.42)	1.28 (1.09, 1.51)	0.0022		
Colon (C18)	Cases	188	557	706	660	2111			
	HR (95%-CI), Model 0	1.00 (Ref.)	1.25 (1.06, 1.48)	1.27 (1.08, 1.49)	1.37 (1.16, 1.61)	1.43 (1.18, 1.74)	0.0002		
	HR (95%-CI), Model 1	1.00 (Ref.)	1.22 (1.03, 1.44)	1.22 (1.04, 1.44)	1.30 (1.10, 1.54)	1.35 (1.11, 1.64)	0.0023		
	HR (95%-CI), Model 2	1.00 (Ref.)	1.19 (1.01, 1.41)	1.18 (1.00, 1.40)	1.25 (1.06, 1.48)	1.28 (1.05, 1.56)	0.0128		
Rectum (C19-20)	Cases	98	267	378	362	1105			
	HR (95%-CI), Model 0	1.00 (Ref.)	1.12 (0.89, 1.42)	1.22 (0.98, 1.53)	1.27 (1.02, 1.60)	1.37 (1.05, 1.78)	0.0210		
	HR (95%-CI), Model 1	1.00 (Ref.)	1.08 (0.86, 1.37)	1.16 (0.92, 1.46)	1.19 (0.94, 1.49)	1.25 (0.95, 1.64)	0.1073		
	HR (95%-CI), Model 2	1.00 (Ref.)	1.08 (0.86, 1.37)	1.16 (0.92, 1.45)	1.18 (0.94, 1.49)	1.24 (0.95, 1.63)	0.1156		
Liver (C22)	Cases	36	69	88	106	299			
	HR (95%-CI), Model 0	1.00 (Ref.)	0.78 (0.52, 1.17)	0.77 (0.52, 1.14)	1.03 (0.70, 1.51)	1.05 (0.64, 1.72)	0.8402		
	HR (95%-CI), Model 1	1.00 (Ref.)	0.84 (0.55, 1.26)	0.84 (0.57, 1.26)	1.10 (0.74, 1.62)	1.14 (0.70, 1.87)	0.5992		
	HR (95%-CI), Model 2	1.00 (Ref.)	0.82 (0.54, 1.24)	0.81 (0.54, 1.21)	1.03 (0.69, 1.53)	1.06 (0.64, 1.74)	0.8285		
Pancreas (C25)	Cases	64	148	221	169	602			
	HR (95%-CI), Model 0	1.00 (Ref.)	0.97 (0.72, 1.30)	1.16 (0.88, 1.54)	1.04 (0.78, 1.40)	1.13 (0.80, 1.59)	0.4984		
	HR (95%-CI), Model 1	1.00 (Ref.)	0.97 (0.72, 1.31)	1.17 (0.88, 1.55)	1.00 (0.74, 1.35)	1.07 (0.75, 1.51)	0.7090		
	HR (95%-CI), Model 2	1.00 (Ref.)	0.95 (0.71, 1.28)	1.13 (0.85, 1.50)	0.96 (0.71, 1.29)	1.01 (0.71, 1.44)	0.9503		
Lung (C34)	Cases	193	495	630	702	2020			
3()	HR (95%-CI), Model 0	1.00 (Ref.)	1.05 (0.89, 1.25)	1.08 (0.91, 1.27)	1.39 (1.19, 1.64)	1.53 (1.26, 1.87)	<0.0001		
	HR (95%-CI), Model 1	1.00 (Ref.)	1.05 (0.89, 1.24)	1.06 (0.90, 1.25)	1.22 (1.03, 1.44)	1.28 (1.05, 1.56)	0.0134		
	HR (95%-CI), Model 2	1.00 (Ref.)	1.07 (0.90, 1.26)	1.09 (0.92, 1.28)	1.25 (1.06, 1.48)	1.33 (1.09, 1.63)	0.0048		
Lung (C34) in never smokers	Total n/cases	33531 / 37	66285 / 74	84646 / 75	71547 / 75	256009 / 261			
	HR (95%-CI), Model 0	1.00 (Ref.)	0.90 (0.61, 1.34)	0.79 (0.53, 1.17)	1.03 (0.69, 1.54)	0.96 (0.59, 1.57)	0.8791		

## S4 Table. Hazard ratios and 95% confidence intervals of cancer incidence by site according to total meat intake in UK Biobank

	HR (95%-CI), Model 2	1.00 (Ref.)	0.93 (0.62, 1.39)	0.82 (0.55, 1.24)	1.08 (0.71, 1.62)	1.02 (0.61, 1.69)	0.9445
Malignant melanoma (C43)	Cases	158	437	547	459	1601	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.24 (1.03, 1.49)	1.22 (1.02, 1.46)	1.18 (0.99, 1.42)	1.20 (0.97, 1.48)	0.0871
	HR (95%-CI), Model 1	1.00 (Ref.)	1.15 (0.96, 1.38)	1.12 (0.94, 1.34)	1.11 (0.92, 1.34)	1.11 (0.90, 1.38)	0.3339
	HR (95%-CI), Model 2	1.00 (Ref.)	1.13 (0.94, 1.36)	1.10 (0.92, 1.32)	1.08 (0.90, 1.31)	1.08 (0.87, 1.34)	0.4936
	HR (95%-CI), Model 3	1.00 (Ref.)	1.12 (0.93, 1.35)	1.08 (0.90, 1.29)	1.06 (0.88, 1.28)	1.05 (0.85, 1.31)	0.6316
Breast (C50) †	Total n/cases	39583 / 791	72017 / 1644	83799 / 1886	56869 / 1280	252268 / 5601	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.10 (1.01, 1.20)	1.10 (1.01, 1.20)	1.12 (1.02, 1.22)	1.14 (1.03, 1.27)	0.0113
	HR (95%-CI), Model 1	1.00 (Ref.)	1.09 (1.00, 1.19)	1.09 (1.00, 1.19)	1.11 (1.02, 1.22)	1.13 (1.02, 1.26)	0.0192
	HR (95%-CI), Model 2	1.00 (Ref.)	1.07 (0.98, 1.16)	1.05 (0.97, 1.15)	1.06 (0.97, 1.17)	1.07 (0.97, 1.20)	0.1876
Endometrium (C54) †	Total n/cases	39583 / 116	72017 / 257	83799 / 292	56869 / 190	252268 / 855	
( ) I	HR (95%-CI), Model 0	1.00 (Ref.)	1.14 (0.91, 1.42)	1.15 (0.93, 1.43)	1.15 (0.91, 1.45)	1.19 (0.91, 1.56)	0.2011
	HR (95%-CI), Model 1	1.00 (Ref.)	1.24 (0.99, 1.55)	1.29 (1.03, 1.61)	1.29 (1.02, 1.64)	1.38 (1.05, 1.82)	0.0201
	HR (95%-CI), Model 2	1.00 (Ref.)	1.14 (0.91, 1.42)	1.11 (0.89, 1.39)	1.05 (0.83, 1.33)	1.07 (0.81, 1.41)	0.6249
Ovary (C56) †	Total n/cases	39583 / 99	72017 / 175	83799 / 168	56869 / 129	252268 / 571	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.90 (0.71, 1.16)	0.76 (0.59, 0.98)	0.89 (0.68, 1.15)	0.79 (0.58, 1.08)	0.1415
	HR (95%-CI), Model 1	1.00 (Ref.)	0.93 (0.72, 1.20)	0.81 (0.62, 1.04)	0.95 (0.72, 1.24)	0.86 (0.63, 1.18)	0.3477
	HR (95%-CI), Model 2	1.00 (Ref.)	0.93 (0.72, 1.19)	0.80 (0.62, 1.04)	0.94 (0.72, 1.24)	0.85 (0.62, 1.17)	0.3287
Prostate (C61) ‡	Total n/cases	18386 / 447	47265 / 1454	69889 / 1919	79612 / 2055	215152 / 5875	0.0207
	HR (95%-CI), Model 0	1.00 (Ref.)	1.11 (0.99, 1.23)	1.05 (0.95, 1.17)	1.09 (0.98, 1.20)	1.07 (0.95, 1.20)	0.2600
	HR (95%-CI), Model 0 HR (95%-CI), Model 1	1.00 (Ref.)	1.07 (0.96, 1.19)	1.01 (0.91, 1.12)	1.06 (0.95, 1.20)	1.04 (0.92, 1.17)	0.2000
		1.00 (Ref.)			( , ,	1.07 (0.95, 1.21)	0.2826
	HR (95%-CI), Model 2		1.07 (0.97, 1.20)	1.03 (0.92, 1.14)	1.08 (0.97, 1.19)		0.2828
(Cold 05)	HR (95%-CI), Model 3	1.00 (Ref.)	1.08 (0.97, 1.20)	1.02 (0.92, 1.14)	1.08 (0.97, 1.19)	1.07 (0.95, 1.20)	0.2935
Kidney (C64-65)		72	198	249	255	774	0 4 5 0 0
	HR (95%-CI), Model 0	1.00 (Ref.)	1.12 (0.85, 1.47)	1.09 (0.84, 1.42)	1.22 (0.94, 1.59)	1.26 (0.92, 1.72)	0.1502
	HR (95%-CI), Model 1	1.00 (Ref.)	1.12 (0.85, 1.47)	1.10 (0.84, 1.44)	1.23 (0.94, 1.61)	1.28 (0.93, 1.76)	0.1329
	HR (95%-CI), Model 2	1.00 (Ref.)	1.06 (0.81, 1.39)	1.01 (0.78, 1.33)	1.11 (0.84, 1.45)	1.11 (0.81, 1.53)	0.5112
Bladder (C67)	Cases	55	154	202	212	623	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.04 (0.76, 1.41)	1.03 (0.76, 1.39)	1.15 (0.85, 1.55)	1.19 (0.84, 1.70)	0.3323
	HR (95%-CI), Model 1	1.00 (Ref.)	0.99 (0.72, 1.35)	0.97 (0.72, 1.32)	1.04 (0.77, 1.42)	1.06 (0.74, 1.52)	0.7477
	HR (95%-CI), Model 2	1.00 (Ref.)	0.97 (0.71, 1.32)	0.95 (0.70, 1.29)	1.01 (0.74, 1.37)	1.01 (0.70, 1.45)	0.9527
Lymphatic and hematopoietic	_						
tissues (C81-96)	Cases	251	673	824	700	2448	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.13 (0.98, 1.31)	1.10 (0.95, 1.27)	1.06 (0.92, 1.23)	1.06 (0.89, 1.25)	0.5294
	HR (95%-CI), Model 1	1.00 (Ref.)	1.14 (0.98, 1.32)	1.11 (0.96, 1.28)	1.08 (0.93, 1.25)	1.08 (0.91, 1.28)	0.4007
	HR (95%-CI), Model 2	1.00 (Ref.)	1.14 (0.98, 1.32)	1.11 (0.96, 1.28)	1.07 (0.92, 1.25)	1.07 (0.90, 1.27)	0.4481
Non-Hodgkin lymphoma (C82-85)	Cases	117	317	407	338	1179	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.15 (0.93, 1.42)	1.18 (0.96, 1.45)	1.13 (0.91, 1.39)	1.15 (0.90, 1.47)	0.2607
	HR (95%-CI), Model 1	1.00 (Ref.)	1.17 (0.94, 1.45)	1.20 (0.97, 1.48)	1.15 (0.93, 1.43)	1.18 (0.92, 1.52)	0.1894
	HR (95%-CI), Model 2	1.00 (Ref.)	1.16 (0.94, 1.44)	1.19 (0.97, 1.47)	1.14 (0.92, 1.42)	1.17 (0.91, 1.51)	0.2158
Multiple myeloma (C90)	Cases	49	127	141	114	431	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.10 (0.79, 1.53)	0.96 (0.70, 1.34)	0.90 (0.64, 1.27)	0.86 (0.58, 1.26)	0.4293
	HR (95%-CI), Model 1	1.00 (Ref.)	1.11 (0.80, 1.55)	0.98 (0.70, 1.36)	0.92 (0.65, 1.30)	0.87 (0.59, 1.30)	0.5000
	HR (95%-CI), Model 2	1.00 (Ref.)	1.11 (0.79, 1.55)	0.97 (0.70, 1.36)	0.91 (0.64, 1.29)	0.86 (0.58, 1.28)	0.4583
		· · ·				,	

Leukaemia (C91-C95)	Cases	78	195	233	205	711	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.03 (0.79, 1.34)	0.97 (0.75, 1.25)	0.94 (0.72, 1.23)	0.91 (0.67, 1.24)	0.5625
	HR (95%-CI), Model 1	1.00 (Ref.)	1.01 (0.77, 1.31)	0.95 (0.73, 1.23)	0.93 (0.71, 1.22)	0.90 (0.66, 1.23)	0.5054
	HR (95%-CI), Model 2	1.00 (Ref.)	1.00 (0.77, 1.31)	0.94 (0.73, 1.23)	0.93 (0.71, 1.22)	0.90 (0.65, 1.23)	0.5076

Bold where p <0.05. CI, Confidence interval; HR, Hazard ratio; LR, likelihood ratio test.

Model 0: Stratified for sex, age group and region and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown).

Model 1: Model 0 + deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current  $\geq$ 15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents,  $\geq$ 50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day,  $\geq$ 20 g/day, unknown), total fruit and vegetable intake (< 3 servings/day, 3-< 4 servings/day, 4-< 6 servings/day,  $\geq$  6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2,  $\geq$ 3, unknown), hormone-replacement therapy use (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown).

Model 2: Model 1 + body mass index (sex-specific quintiles, unknown).

Model 3: For malignant melanoma: Model 2 + skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black, other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year, ≥3 times/year, unknown); for prostate cancer: Model 2 + enlarged prostate (yes, no, unknown).

\* In 22 cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

† Analyses restricted to women.

‡Analyses restricted to men.

		Red an	d processed meat in	take (times/week), (	mean g/day)		
Site (ICD-10)	Model					per 70 g higher	
		≤1 (10.5)	>1-<3 (48.7)	3-<5 (65.0)	≥5 (79.3)	intake	P <sub>trend</sub>
	Total n	44027	160080	140683	122987	467777	
Oral (C00-C14)	Cases	41	168	170	171	550	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.02 (0.73, 1.44)	1.07 (0.76, 1.51)	1.12 (0.79, 1.58)	1.15 (0.83, 1.59)	0.4151
	HR (95%-CI), Model 1	1.00 (Ref.)	1.04 (0.74, 1.48)	1.02 (0.72, 1.45)	0.97 (0.68, 1.38)	0.94 (0.68, 1.31)	0.7202
	HR (95%-CI), Model 2	1.00 (Ref.)	1.07 (0.76, 1.52)	1.06 (0.74, 1.50)	1.01 (0.70, 1.44)	0.98 (0.70, 1.36)	0.8807
Oesophagus (C15)	Cases	32	149	158	187	526	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.02 (0.70, 1.50)	1.07 (0.73, 1.56)	1.26 (0.86, 1.84)	1.35 (0.95, 1.93)	0.0939
	HR (95%-CI), Model 1	1.00 (Ref.)	1.02 (0.69, 1.51)	1.02 (0.69, 1.51)	1.13 (0.76, 1.66)	1.16 (0.81, 1.65)	0.4257
	HR (95%-CI), Model 2	1.00 (Ref.)	0.99 (0.67, 1.46)	0.97 (0.66, 1.44)	1.06 (0.72, 1.57)	1.09 (0.76, 1.56)	0.6516
Stomach (C16)	Cases	29	90	115	114	348	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.67 (0.44, 1.02)	0.86 (0.57, 1.30)	0.87 (0.58, 1.32)	1.08 (0.71, 1.64)	0.7238
	HR (95%-CI), Model 1	1.00 (Ref.)	0.70 (0.46, 1.07)	0.88 (0.58, 1.33)	0.85 (0.56, 1.30)	1.02 (0.66, 1.55)	0.9393
	HR (95%-CI), Model 2	1.00 (Ref.)	0.67 (0.44, 1.03)	0.84 (0.55, 1.28)	0.81 (0.53, 1.24)	0.96 (0.63, 1.48)	0.8673
Colorectum (C18-20)*	Cases	197	1002	985	1016	3200	
. ,	HR (95%-CI), Model 0	1.00 (Ref.)	1.21 (1.04, 1.41)	1.29 (1.10, 1.50)	1.44 (1.24, 1.68)	1.45 (1.26, 1.67)	<0.0001
	HR (95%-CI), Model 1	1.00 (Ref.)	1.18 (1.01, 1.37)	1.23 (1.05, 1.44)	1.35 (1.15, 1.58)	1.36 (1.17, 1.57)	<0.0001
	HR (95%-CI), Model 2	1.00 (Ref.)	1.15 (0.99, 1.35)	1.20 (1.02, 1.40)	1.31 (1.12, 1.54)	1.31 (1.14, 1.52)	0.0002
Colon (C18)	Cases	125	674	660	655	2114	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.30 (1.07, 1.57)	1.41 (1.16, 1.71)	1.54 (1.27, 1.87)	1.53 (1.28, 1.82)	<0.0001
	HR (95%-CI), Model 1	1.00 (Ref.)	1.27 (1.05, 1.54)	1.36 (1.12, 1.65)	1.47 (1.21, 1.79)	1.45 (1.21, 1.73)	<0.0001
	HR (95%-CI), Model 2	1.00 (Ref.)	1.24 (1.02, 1.51)	1.31 (1.08, 1.59)	1.41 (1.15, 1.72)	1.38 (1.16, 1.66)	0.0004
Rectum (C19-20)	Cases	73	340	327	368	1108	
,	HR (95%-CI), Model 0	1.00 (Ref.)	1.09 (0.84, 1.40)	1.08 (0.84, 1.40)	1.28 (0.99, 1.65)	1.30 (1.03, 1.65)	0.0296
	HR (95%-CI), Model 1	1.00 (Ref.)	1.03 (0.80, 1.34)	1.01 (0.78, 1.30)	1.16 (0.89, 1.50)	1.18 (0.92, 1.50)	0.1937
	HR (95%-CI), Model 2	1.00 (Ref.)	1.03 (0.80, 1.33)	1.00 (0.77, 1.30)	1.15 (0.89, 1.50)	1.17 (0.92, 1.50)	0.2060
Liver (C22)	Cases	28	86	86	99	299	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.71 (0.46, 1.09)	0.74 (0.48, 1.14)	0.90 (0.59, 1.39)	1.02 (0.65, 1.58)	0.9427
	HR (95%-CI), Model 1	1.00 (Ref.)	0.79 (0.51, 1.23)	0.82 (0.52, 1.27)	0.97 (0.62, 1.51)	1.06 (0.68, 1.65)	0.8120
	HR (95%-CI), Model 2	1.00 (Ref.)	0.77 (0.50, 1.20)	0.78 (0.50, 1.21)	0.91 (0.58, 1.42)	0.98 (0.63, 1.54)	0.9362
Pancreas (C25)	Cases	41	197	191	175	604	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.15 (0.82, 1.61)	1.23 (0.88, 1.73)	1.26 (0.89, 1.78)	1.27 (0.93, 1.75)	0.1370
	HR (95%-CI), Model 1	1.00 (Ref.)	1.15 (0.82, 1.62)	1.20 (0.85, 1.70)	1.17 (0.82, 1.66)	1.14 (0.83, 1.58)	0.4167
	HR (95%-CI), Model 2	1.00 (Ref.)	1.12 (0.80, 1.58)	1.16 (0.82, 1.64)	1.11 (0.78, 1.59)	1.09 (0.79, 1.51)	0.6087
Lung (C34)	Cases	108	602	608	706	2024	0.000
	HR (95%-CI), Model 0	1.00 (Ref.)	1.32 (1.07, 1.61)	1.47 (1.20, 1.81)	1.86 (1.52, 2.28)	1.97 (1.64, 2.37)	<0.0001
	HR (95%-CI), Model 1	1.00 (Ref.)	1.29 (1.05, 1.59)	1.31 (1.06, 1.61)	1.44 (1.17, 1.77)	1.37 (1.14, 1.65)	0.0008
	HR (95%-CI), Model 2	1.00 (Ref.)	1.32 (1.08, 1.63)	1.34 (1.09, 1.66)	1.49 (1.20, 1.83)	1.41 (1.17, 1.70)	0.0002
Lung (C34) in never smokers	Total n/cases	26348 / 25	90453 / 110	76690 / 64	62691 / 62	256182 / 261	0.0002
	HR (95%-CI), Model 0	1.00 (Ref.)	1.14 (0.74, 1.77)	0.83 (0.52, 1.32)	1.00 (0.62, 1.60)	0.86 (0.55, 1.33)	0.4861
	HR (95%-CI), Model 1	1.00 (Ref.)	1.17 (0.75, 1.83)	0.84 (0.52, 1.32)	1.00 (0.62, 1.60)	0.85 (0.54, 1.34)	0.4801
		1.00 (Nel.)	1.17(0.75, 1.05)	0.04 (0.02, 1.00)	1.00 (0.02, 1.02)	0.00 (0.04, 1.04)	0.4010

S5 Table. Hazard ratios and 95% confidence intervals of cancer incidence by site according to red and processed meat intake in UK Biobank

Malignant melanoma (C43)	HR (95%-CI), Model 2 Cases	1.00 (Ref.) 98	1.18 (0.76, 1.85) 553	0.86 (0.53, 1.38) 550	1.03 (0.63, 1.68) 400	0.88 (0.56, 1.38) 1601	0.5742
	HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2 HR (95%-CI), Model 3	1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	1.43 (1.16, 1.78) 1.31 (1.05, 1.63) 1.29 (1.04, 1.60) 1.27 (1.03, 1.58)	1.59 (1.28, 1.98) 1.45 (1.16, 1.80) 1.41 (1.13, 1.76) 1.40 (1.12, 1.74)	<b>1.31 (1.05, 1.64)</b> 1.21 (0.97, 1.52) 1.18 (0.94, 1.49) 1.17 (0.93, 1.47)	<b>1.23 (1.01, 1.49)</b> 1.16 (0.95, 1.42) 1.13 (0.93, 1.38) 1.12 (0.92, 1.37)	<b>0.0348</b> 0.1363 0.2175 0.2536
Breast (C50) †	Total n/cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	31323 / 615 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	101755 / 2227 1.08 (0.99, 1.18) 1.06 (0.97, 1.16) 1.04 (0.95, 1.13)	71684 / 1650 <b>1.14 (1.03, 1.25)</b> <b>1.11 (1.01, 1.22)</b> 1.07 (0.97, 1.18)	47660 / 1111 <b>1.14 (1.04, 1.26)</b> <b>1.12 (1.01, 1.24)</b> 1.07 (0.97, 1.19)	252422 / 5603 <b>1.16 (1.05, 1.27)</b> <b>1.13 (1.03, 1.25)</b> 1.08 (0.98, 1.19)	<b>0.0024</b> <b>0.0120</b> 0.1087
Endometrium (C54) †	Total n/cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	31323 / 87 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	101755 / 353 1.16 (0.92, 1.47) <b>1.29 (1.02, 1.64)</b> 1.18 (0.92, 1.50)	71684 / 261 1.24 (0.97, 1.58) <b>1.40 (1.09, 1.79)</b> 1.19 (0.93, 1.53)	47660 / 155 1.09 (0.84, 1.42) 1.24 (0.95, 1.63) 1.02 (0.78, 1.34)	252422 / 856 1.12 (0.88, 1.43) 1.27 (0.99, 1.62) 1.03 (0.80, 1.32)	0.3480 0.0607 0.8419
Ovary (C56) †	Total n/cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	31323 / 75 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	101755 / 246 0.95 (0.73, 1.23) 0.98 (0.76, 1.28) 0.98 (0.75, 1.28)	71684 / 145 0.79 (0.60, 1.05) 0.84 (0.63, 1.12) 0.84 (0.63, 1.11)	47660 / 105 0.85 (0.63, 1.14) 0.91 (0.67, 1.23) 0.90 (0.66, 1.23)	252422 / 571 0.79 (0.60, 1.05) 0.85 (0.64, 1.14) 0.85 (0.63, 1.14)	0.1057 0.2790 0.2663
Prostate (C61) ‡	Total n/cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2 HR (95%-CI), Model 3	12704 / 259 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	58325 / 1687 1.22 (1.07, 1.39) 1.17 (1.02, 1.33) 1.18 (1.03, 1.34) 1.18 (1.03, 1.34)	68999 / 1931 1.21 (1.06, 1.38) 1.16 (1.02, 1.33) 1.18 (1.03, 1.35) 1.18 (1.03, 1.35)	75327 / 2000 1.16 (1.02, 1.32) 1.12 (0.98, 1.28) 1.15 (1.01, 1.31) 1.15 (1.01, 1.31)	215355 / 5877 1.05 (0.94, 1.16) 1.04 (0.93, 1.16) 1.07 (0.96, 1.19) 1.07 (0.96, 1.19)	0.3929 0.4718 0.2488 0.2375
Kidney (C64-65)	Cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	50 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	243 1.12 (0.83, 1.52) 1.11 (0.82, 1.52) 1.04 (0.76, 1.42)	238 1.15 (0.84, 1.56) 1.14 (0.83, 1.55) 1.03 (0.76, 1.42)	245 1.24 (0.91, 1.68) 1.23 (0.90, 1.69) 1.09 (0.79, 1.50)	776 1.24 (0.93, 1.64) 1.23 (0.92, 1.64) 1.09 (0.81, 1.46)	0.1424 0.1616 0.5636
Bladder (C67)	Cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	31 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	190 1.27 (0.87, 1.86) 1.19 (0.81, 1.74) 1.16 (0.79, 1.70)	197 1.28 (0.88, 1.88) 1.15 (0.78, 1.70) 1.11 (0.76, 1.64)	205 1.33 (0.91, 1.95) 1.14 (0.77, 1.68) 1.09 (0.74, 1.61)	623 1.25 (0.90, 1.73) 1.05 (0.75, 1.46) 1.00 (0.72, 1.40)	0.1796 0.7756 0.9814
Lymphatic and hematopoietic							
tissues (C81-96)	Cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	191 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	837 1.05 (0.90, 1.23) 1.05 (0.89, 1.23) 1.04 (0.89, 1.22)	754 1.03 (0.87, 1.20) 1.03 (0.87, 1.21) 1.02 (0.87, 1.21)	669 0.99 (0.84, 1.17) 1.00 (0.85, 1.18) 0.99 (0.84, 1.17)	2451 0.97 (0.83, 1.13) 0.98 (0.84, 1.14) 0.97 (0.83, 1.14)	0.7011 0.7841 0.7151
Non-Hodgkin lymphoma (C82-85)	Cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	95 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	388 0.99 (0.79, 1.23) 1.00 (0.79, 1.25) 0.99 (0.79, 1.25)	361 1.01 (0.80, 1.27) 1.02 (0.81, 1.29) 1.01 (0.80, 1.28)	337 1.04 (0.83, 1.31) 1.06 (0.83, 1.34) 1.05 (0.82, 1.33)	1181 1.06 (0.85, 1.32) 1.07 (0.86, 1.35) 1.06 (0.85, 1.34)	0.5906 0.5333 0.5874
Multiple myeloma (C90)	Cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 1	31 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	161 1.26 (0.85, 1.85) 1.27 (0.86, 1.88) 1.27 (0.86, 1.87)	134 1.14 (0.77, 1.69) 1.17 (0.79, 1.75) 1.16 (0.78, 1.74)	106 1.00 (0.66, 1.50) 1.03 (0.68, 1.56) 1.02 (0.67, 1.54)	432 0.90 (0.63, 1.28) 0.93 (0.64, 1.34) 0.92 (0.63, 1.32)	0.5452 0.6861 0.6355

Leukaemia (C91-C95)	Cases	57	245	219	190	711	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.99 (0.74, 1.33)	0.94 (0.70, 1.26)	0.87 (0.64, 1.17)	0.84 (0.64, 1.11)	0.2181
	HR (95%-CI), Model 1	1.00 (Ref.)	0.95 (0.71, 1.27)	0.90 (0.66, 1.21)	0.83 (0.61, 1.13)	0.81 (0.61, 1.08)	0.1459
	HR (95%-CI), Model 2	1.00 (Ref.)	0.95 (0.71, 1.27)	0.89 (0.66, 1.21)	0.83 (0.61, 1.13)	0.81 (0.60, 1.08)	0.1460

Bold where p <0.05. CI, Confidence interval; HR, Hazard ratio; LR, likelihood ratio test.

Model 0: Stratified for sex, age group and region and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown).

Model 1: Model 0 + deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current  $\geq$ 15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents,  $\geq$ 50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day,  $\geq$ 20 g/day, unknown), total fruit and vegetable intake (< 3 servings/day, 3-< 4 servings/day, 4-< 6 servings/day,  $\geq$  6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2,  $\geq$ 3, unknown), hormone-replacement therapy use (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown).

Model 2: Model 1 + body mass index (sex-specific quintiles, unknown).

Model 3: For malignant melanoma: Model 2 + skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black, other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year, ≥3 times/year, unknown); for prostate cancer: Model 2 + enlarged prostate (yes, no, unknown).

\* In 22 cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

† Analyses restricted to women.

‡ Analyses restricted to men.

		Red meat intake (times/week), (mean g/day)									
Site (ICD-10)	Model		·		• ·	per 50 g higher					
		<1 (6.5)	1-<2 (32.6)	2-<3 (45.1)	≥3 (55.1)	intake	Ptrend				
	Total n	47725	184629	173889	62121	468364					
Oral (C00-C14)	Cases	53	195	218	84	550					
	HR (95%-CI), Model 0	1.00 (Ref.)	0.85 (0.62, 1.15)	0.95 (0.70, 1.28)	0.97 (0.69, 1.38)	1.05 (0.75, 1.46)	0.7928				
	HR (95%-CI), Model 1	1.00 (Ref.)	0.85 (0.63, 1.16)	0.93 (0.68, 1.26)	0.87 (0.61, 1.24)	0.94 (0.67, 1.32)	0.7216				
	HR (95%-CI), Model 2	1.00 (Ref.)	0.88 (0.64, 1.19)	0.96 (0.70, 1.30)	0.90 (0.63, 1.29)	0.97 (0.69, 1.36)	0.8714				
Oesophagus (C15)	Cases	37	189	221	80	527					
	HR (95%-CI), Model 0	1.00 (Ref.)	1.03 (0.73, 1.47)	1.13 (0.80, 1.61)	1.07 (0.73, 1.59)	1.14 (0.80, 1.64)	0.4606				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.04 (0.73, 1.49)	1.13 (0.79, 1.61)	1.00 (0.67, 1.49)	1.06 (0.74, 1.52)	0.7473				
	HR (95%-CI), Model 2	1.00 (Ref.)	1.01 (0.71, 1.44)	1.08 (0.75, 1.54)	0.94 (0.63, 1.41)	1.00 (0.70, 1.44)	0.9913				
Stomach (C16)	Cases	28	117	147	58	350					
	HR (95%-CI), Model 0	1.00 (Ref.)	0.85 (0.56, 1.28)	1.01 (0.67, 1.52)	1.05 (0.66, 1.65)	1.20 (0.77, 1.87)	0.4244				
	HR (95%-CI), Model 1	1.00 (Ref.)	0.89 (0.59, 1.36)	1.06 (0.70, 1.61)	1.05 (0.66, 1.67)	1.20 (0.77, 1.87)	0.4279				
	HR (95%-CI), Model 2	1.00 (Ref.)	0.87 (0.57, 1.32)	1.02 (0.68, 1.55)	1.01 (0.63, 1.60)	1.14 (0.73, 1.79)	0.5601				
Colorectum (C18-20)*	Cases	228	1184	1282	507	3201					
, , , , , , , , , , , , , , , , , , ,	HR (95%-CI), Model 0	1.00 (Ref.)	1.16 (1.01, 1.34)	1.24 (1.07, 1.43)	1.34 (1.15, 1.57)	1.35 (1.16, 1.56)	0.0001				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.12 (0.97, 1.29)	1.17 (1.02, 1.36)	1.26 (1.07, 1.48)	1.26 (1.08, 1.46)	0.0026				
	HR (95%-CI), Model 2	1.00 (Ref.)	1.10 (0.95, 1.27)	1.15 (0.99, 1.33)	1.22 (1.04, 1.44)	1.22 (1.05, 1.42)	0.0091				
Colon (C18)	Cases	142	780	853	339	2114					
	HR (95%-CI), Model 0	1.00 (Ref.)	1.25 (1.04, 1.49)	1.35 (1.13, 1.62)	1.48 (1.21, 1.80)	1.47 (1.23, 1.76)	<0.0001				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.22 (1.02, 1.46)	1.30 (1.09, 1.56)	1.41 (1.15, 1.72)	1.39 (1.16, 1.67)	0.0004				
	HR (95%-CI), Model 2	1.00 (Ref.)	1.19 (0.99, 1.43)	1.26 (1.05, 1.51)	1.35 (1.10, 1.65)	1.34 (1.11, 1.61)	0.0021				
Rectum (C19-20)	Cases	87	417	435	170	1109					
	HR (95%-CI), Model 0	1.00 (Ref.)	1.03 (0.82, 1.30)	1.05 (0.83, 1.33)	1.13 (0.87, 1.47)	1.12 (0.88, 1.43)	0.3559				
	HR (95%-CI), Model 1	1.00 (Ref.)	0.98 (0.77, 1.23)	0.97 (0.77, 1.23)	1.02 (0.78, 1.33)	1.01 (0.79, 1.30)	0.9091				
	HR (95%-CI), Model 2	1.00 (Ref.)	0.97 (0.77, 1.23)	0.97 (0.76, 1.23)	1.02 (0.78, 1.33)	1.01 (0.79, 1.30)	0.9380				
Liver (C22)	Cases	25	106	122	48	301					
	HR (95%-CI), Model 0	1.00 (Ref.)	0.92 (0.59, 1.43)	1.03 (0.67, 1.58)	1.10 (0.68, 1.79)	1.18 (0.74, 1.88)	0.4985				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.05 (0.67, 1.63)	1.19 (0.76, 1.86)	1.21 (0.74, 1.99)	1.30 (0.81, 2.07)	0.2782				
	HR (95%-CI), Model 2	1.00 (Ref.)	1.02 (0.66, 1.60)	1.15 (0.73, 1.80)	1.15 (0.70, 1.90)	1.23 (0.77, 1.97)	0.3945				
Pancreas (C25)	Cases	46	224	258	76	604					
	HR (95%-CI), Model 0	1.00 (Ref.)	1.09 (0.79, 1.50)	1.25 (0.91, 1.72)	1.05 (0.72, 1.51)	1.18 (0.85, 1.64)	0.3281				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.09 (0.79, 1.51)	1.23 (0.89, 1.70)	0.98 (0.67, 1.43)	1.10 (0.79, 1.54)	0.5605				
	HR (95%-CI), Model 2	1.00 (Ref.)	1.07 (0.77, 1.47)	1.19 (0.86, 1.65)	0.94 (0.65, 1.37)	1.06 (0.76, 1.48)	0.7446				
Lung (C34)	Cases	137	720	795	375	2027					

## S6 Table. Hazard ratios and 95% confidence intervals of cancer incidence by site according to red meat intake in UK Biobank

	HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	1.18 (0.98, 1.41) 1.14 (0.95, 1.38) 1.17 (0.97, 1.40)	<b>1.27 (1.05, 1.52)</b> 1.17 (0.97, 1.41) 1.20 (1.00, 1.44)	1.59 (1.30, 1.93) 1.30 (1.06, 1.59) 1.34 (1.09, 1.63)	1.57 (1.31, 1.90) 1.27 (1.05, 1.53) 1.30 (1.08, 1.57)	<0.0001 0.0124 0.0055
Lung (C34) in never smokers	Total n/cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	28308 / 27 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	102391 / 112 1.06 (0.70, 1.62) 1.07 (0.70, 1.64) 1.08 (0.70, 1.66)	93745 / 82 0.81 (0.52, 1.25) 0.82 (0.52, 1.28) 0.83 (0.53, 1.31)	32101 / 41 1.15 (0.71, 1.88) 1.15 (0.70, 1.90) 1.18 (0.71, 1.95)	256545 / 262 0.91 (0.57, 1.45) 0.92 (0.57, 1.48) 0.95 (0.58, 1.53)	0.6970 0.7302 0.8181
Malignant melanoma (C43)	Cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2 HR (95%-CI), Model 3	107 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	657 1.47 (1.20, 1.80) 1.36 (1.10, 1.67) 1.34 (1.09, 1.64) 1.32 (1.07, 1.62)	655 1.50 (1.22, 1.84) 1.36 (1.11, 1.68) 1.33 (1.08, 1.64) 1.31 (1.07, 1.62)	185 1.19 (0.94, 1.52) 1.13 (0.88, 1.44) 1.10 (0.86, 1.40) 1.09 (0.85, 1.39)	1604 1.21 (0.99, 1.47) 1.13 (0.92, 1.38) 1.10 (0.89, 1.35) 1.09 (0.88, 1.34)	0.0649 0.2563 0.3683 0.4366
Breast (C50) †	Total n/cases HR (95%-Cl), Model 0 HR (95%-Cl), Model 1 HR (95%-Cl), Model 2	31964 / 632 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	103136 / 2207 1.05 (0.96, 1.15) 1.04 (0.95, 1.13) 1.01 (0.93, 1.11)	88315 / 2063 1.13 (1.03, 1.23) 1.10 (1.01, 1.21) 1.07 (0.98, 1.17)	29330 / 710 <b>1.16 (1.04, 1.30)</b> <b>1.15 (1.03, 1.28)</b> 1.11 (0.99, 1.23)	252745 / 5612 1.19 (1.07, 1.31) 1.17 (1.05, 1.29) 1.12 (1.01, 1.24)	0.0008 0.0033 0.0299
Endometrium (C54) †	Total n/cases HR (95%-Cl), Model 0 HR (95%-Cl), Model 1 HR (95%-Cl), Model 2	31964 / 89 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	103136 / 347 1.13 (0.90, 1.43) 1.24 (0.98, 1.58) 1.13 (0.89, 1.44)	88315 / 327 1.20 (0.95, 1.52) <b>1.37 (1.08, 1.75)</b> 1.19 (0.93, 1.52)	29330 / 93 1.02 (0.76, 1.37) 1.17 (0.87, 1.57) 0.99 (0.73, 1.33)	252745 / 856 1.11 (0.86, 1.44) 1.29 (1.00, 1.68) 1.08 (0.83, 1.40)	0.4074 0.0545 0.5739
Ovary (C56) †	Total n/cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	31964 / 84 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	103136 / 234 0.81 (0.63, 1.04) 0.83 (0.65, 1.07) 0.83 (0.64, 1.07)	88315 / 182 0.71 (0.55, 0.92) 0.75 (0.57, 0.98) 0.75 (0.57, 0.97)	29330 / 73 0.85 (0.62, 1.16) 0.90 (0.65, 1.24) 0.90 (0.65, 1.24)	252745 / 573 <b>0.74 (0.55, 0.99)</b> 0.80 (0.59, 1.08) 0.79 (0.58, 1.08)	<b>0.0461</b> 0.1441 0.1346
Prostate (C61) ‡	Cases HR (95%-Cl), Model 0 HR (95%-Cl), Model 1 HR (95%-Cl), Model 2 HR (95%-Cl), Model 3	15761 / 294 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	81493 / 2213 1.29 (1.14, 1.46) 1.23 (1.09, 1.39) 1.25 (1.10, 1.41) 1.25 (1.10, 1.41)	85574 / 2495 1.31 (1.16, 1.48) 1.25 (1.11, 1.42) 1.27 (1.13, 1.44) 1.28 (1.13, 1.44)	32791 / 884 1.23 (1.08, 1.40) 1.18 (1.03, 1.35) 1.21 (1.05, 1.38) 1.21 (1.06, 1.38)	215619 / 5886 1.16 (1.04, 1.30) 1.13 (1.01, 1.26) 1.15 (1.03, 1.29) 1.16 (1.03, 1.30)	0.0087 0.0396 0.0151 0.0134
Kidney (C64-65)	Cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	60 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	283 1.02 (0.77, 1.35) 1.02 (0.77, 1.35) 0.95 (0.72, 1.27)	315 1.10 (0.83, 1.45) 1.12 (0.84, 1.48) 1.03 (0.77, 1.36)	118 1.12 (0.82, 1.53) 1.13 (0.82, 1.55) 1.01 (0.74, 1.40)	776 1.17 (0.87, 1.56) 1.19 (0.89, 1.61) 1.07 (0.79, 1.45)	0.3004 0.2449 0.6513
Bladder (C67)	Cases HR (95%-Cl), Model 0 HR (95%-Cl), Model 1 HR (95%-Cl), Model 2	37 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	238 1.23 (0.87, 1.74) 1.16 (0.82, 1.65) 1.13 (0.80, 1.61)	252 1.22 (0.86, 1.73) 1.13 (0.80, 1.61) 1.10 (0.77, 1.56)	99 1.31 (0.90, 1.92) 1.17 (0.79, 1.72) 1.12 (0.76, 1.65)	626 1.23 (0.88, 1.72) 1.10 (0.78, 1.55) 1.06 (0.75, 1.49)	0.2302 0.5776 0.7464
Lymphatic and hematopoietic	Cases	215	922	989	327	2453	

tissues (C81-96)							
	HR (95%-CI), Model 0	1.00 (Ref.)	0.97 (0.83, 1.12)	1.03 (0.89, 1.19)	0.95 (0.80, 1.13)	1.01 (0.86, 1.19)	0.8993
	HR (95%-CI), Model 1	1.00 (Ref.)	0.97 (0.83, 1.12)	1.04 (0.90, 1.21)	0.96 (0.81, 1.15)	1.03 (0.87, 1.21)	0.7272
	HR (95%-CI), Model 2	1.00 (Ref.)	0.96 (0.83, 1.12)	1.04 (0.89, 1.21)	0.95 (0.80, 1.14)	1.02 (0.87, 1.20)	0.7888
Non-Hodgkin lymphoma (C82-85)	Cases	99	435	483	165	1182	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.00 (0.80, 1.24)	1.11 (0.89, 1.38)	1.06 (0.83, 1.37)	1.14 (0.91, 1.44)	0.2594
	HR (95%-CI), Model 1	1.00 (Ref.)	1.01 (0.81, 1.27)	1.13 (0.91, 1.41)	1.09 (0.84, 1.41)	1.17 (0.92, 1.49)	0.1914
	HR (95%-CI), Model 2	1.00 (Ref.)	1.01 (0.81, 1.26)	1.13 (0.90, 1.41)	1.08 (0.84, 1.40)	1.16 (0.92, 1.48)	0.2158
Multiple myeloma (C90)	Cases	35	185	163	49	432	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.20 (0.84, 1.73)	1.06 (0.73, 1.53)	0.90 (0.58, 1.40)	0.87 (0.60, 1.26)	0.4495
	HR (95%-CI), Model 1	1.00 (Ref.)	1.21 (0.84, 1.74)	1.08 (0.74, 1.57)	0.91 (0.58, 1.41)	0.88 (0.60, 1.28)	0.5031
	HR (95%-CI), Model 2	1.00 (Ref.)	1.20 (0.83, 1.74)	1.07 (0.74, 1.56)	0.90 (0.57, 1.40)	0.87 (0.59, 1.27)	0.4678
Leukaemia (C91-C95)	Cases	71	256	291	94	712	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.78 (0.60, 1.02)	0.87 (0.67, 1.13)	0.77 (0.56, 1.05)	0.86 (0.64, 1.15)	0.3141
	HR (95%-CI), Model 1	1.00 (Ref.)	0.76 (0.58, 0.99)	0.85 (0.65, 1.11)	0.76 (0.55, 1.04)	0.85 (0.63, 1.15)	0.3052
	HR (95%-CI), Model 2	1.00 (Ref.)	0.75 (0.58, 0.98)	0.85 (0.65, 1.11)	0.76 (0.55, 1.04)	0.85 (0.63, 1.15)	0.3019

Bold where p <0.05. CI, Confidence interval; HR, Hazard ratio; LR, likelihood ratio test.

Model 0: Stratified for sex, age group and region and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown).

Model 1: Model 0 + deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current  $\geq$ 15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents,  $\geq$ 50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day,  $\geq$ 20 g/day, unknown), total fruit and vegetable intake (< 3 servings/day, 3-< 4 servings/day, 4-< 6 servings/day,  $\geq$ 6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2,  $\geq$ 3, unknown), hormone-replacement therapy use (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown). Model 2: Model 1 + body mass index (sex-specific quintiles, unknown).

Model 3: For malignant melanoma: Model 2 + skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black, other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year, ≥3 times/year, unknown); for prostate cancer: Model 2 + enlarged prostate (yes, no, unknown).

\* In 22 cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

† Analyses restricted to women.

‡ Analyses restricted to men.

		Pro	ocessed meat intake	(times/week), (mea	n g/day)		
Site (ICD-10)	Model				5	per 20 g higher	
		0 (4.1)	>0-<1 (15.6)	1-<2 (21.3)	≥2 (29.1)	intake	Ptrend
	Total n	44046	143524	138083	147228	472881	
Oral (C00-C14)	Cases	48	128	177	205	558	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.76 (0.55, 1.06)	0.98 (0.71, 1.36)	0.96 (0.70, 1.33)	1.11 (0.87, 1.41)	0.4054
	HR (95%-CI), Model 1	1.00 (Ref.)	0.77 (0.55, 1.08)	0.96 (0.69, 1.33)	0.83 (0.59, 1.15)	0.93 (0.73, 1.19)	0.5650
	HR (95%-CI), Model 2	1.00 (Ref.)	0.79 (0.57, 1.11)	0.99 (0.71, 1.38)	0.86 (0.61, 1.19)	0.95 (0.75, 1.21)	0.6892
Oesophagus (C15)	Cases	35	128	152	219	534	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.95 (0.65, 1.37)	0.99 (0.68, 1.43)	1.18 (0.82, 1.70)	1.25 (0.97, 1.61)	0.0791
	HR (95%-CI), Model 1	1.00 (Ref.)	0.93 (0.64, 1.36)	0.93 (0.64, 1.36)	1.02 (0.70, 1.48)	1.08 (0.83, 1.39)	0.5729
	HR (95%-CI), Model 2	1.00 (Ref.)	0.90 (0.62, 1.32)	0.89 (0.61, 1.30)	0.97 (0.66, 1.40)	1.03 (0.80, 1.34)	0.7947
Stomach (C16)	Cases	28	86	105	134	353	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.78 (0.51, 1.20)	0.86 (0.56, 1.31)	0.94 (0.62, 1.42)	1.08 (0.79, 1.46)	0.6376
	HR (95%-CI), Model 1	1.00 (Ref.)	0.81 (0.53, 1.25)	0.86 (0.56, 1.33)	0.89 (0.58, 1.37)	1.00 (0.73, 1.36)	0.9995
	HR (95%-CI), Model 2	1.00 (Ref.)	0.79 (0.51, 1.22)	0.83 (0.54, 1.28)	0.86 (0.56, 1.31)	0.97 (0.71, 1.32)	0.8474
Colorectum (C18-20)*	Cases	211	905	963	1149	3228	
,	HR (95%-CI), Model 0	1.00 (Ref.)	1.19 (1.02, 1.38)	1.25 (1.07, 1.45)	1.36 (1.17, 1.58)	1.25 (1.13, 1.39)	<0.0001
	HR (95%-CI), Model 1	1.00 (Ref.)	1.15 (0.99, 1.34)	1.20 (1.03, 1.40)	1.28 (1.10, 1.50)	1.20 (1.08, 1.33)	0.0006
	HR (95%-CI), Model 2	1.00 (Ref.)	1.13 (0.97, 1.32)	1.17 (1.00, 1.36)	1.25 (1.07, 1.46)	1.18 (1.06, 1.31)	0.0022
Colon (C18)	Cases	145	621	649	719	2134	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.20 (1.00, 1.43)	1.27 (1.06, 1.52)	1.32 (1.10, 1.58)	1.21 (1.07, 1.37)	0.0025
	HR (95%-CI), Model 1	1.00 (Ref.)	1.17 (0.97, 1.40)	1.22 (1.02, 1.47)	1.26 (1.05, 1.52)	1.17 (1.03, 1.32)	0.0167
	HR (95%-CI), Model 2	1.00 (Ref.)	1.14 (0.95, 1.37)	1.18 (0.98, 1.42)	1.21 (1.00, 1.46)	1.13 (1.00, 1.29)	0.0575
Rectum (C19-20)	Cases	68	289	322	437	1116	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.16 (0.89, 1.51)	1.21 (0.93, 1.57)	1.42 (1.10, 1.85)	1.34 (1.13, 1.60)	0.0009
	HR (95%-CI), Model 1	1.00 (Ref.)	1.11 (0.85, 1.45)	1.14 (0.87, 1.49)	1.31 (1.00, 1.71)	1.26 (1.06, 1.51)	0.0104
	HR (95%-CI), Model 2	1.00 (Ref.)	1.11 (0.85, 1.45)	1.14 (0.87, 1.49)	1.31 (1.00, 1.71)	1.26 (1.06, 1.51)	0.0106
Liver (C22)	Cases	27	85	76	114	302	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.86 (0.55, 1.32)	0.72 (0.46, 1.13)	0.96 (0.62, 1.47)	1.03 (0.75, 1.43)	0.8388
	HR (95%-CI), Model 1	1.00 (Ref.)	0.96 (0.61, 1.49)	0.80 (0.50, 1.26)	1.01 (0.65, 1.58)	1.04 (0.75, 1.44)	0.8205
	HR (95%-CI), Model 2	1.00 (Ref.)	0.93 (0.60, 1.45)	0.76 (0.48, 1.21)	0.95 (0.61, 1.49)	0.99 (0.71, 1.38)	0.9467
Pancreas (C25)	Cases	43	189	166	210	608	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.23 (0.89, 1.72)	1.09 (0.78, 1.53)	1.30 (0.93, 1.82)	1.17 (0.93, 1.47)	0.1823
	HR (95%-CI), Model 1	1.00 (Ref.)	1.22 (0.87, 1.71)	1.06 (0.75, 1.49)	1.19 (0.84, 1.67)	1.07 (0.84, 1.35)	0.5953
	HR (95%-CI), Model 2	1.00 (Ref.)	1.19 (0.85, 1.67)	1.02 (0.72, 1.44)	1.14 (0.80, 1.60)	1.03 (0.81, 1.31)	0.7995
Lung (C34)	Cases	143	514	593	817	2067	
- · · ·							

- 37 Table. Hazaru talius anu 3370 cumuence milervais ur cancer miciuence by sile accuruing lu processeu meal milare in UN biubank	S7 Table. Hazard ratios and 95% confidence intervals of cancer incidence b	v site according to processed meat intake in UK Biobank
--	--	---

	HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	0.99 (0.83, 1.20) 0.97 (0.80, 1.17) 0.99 (0.82, 1.19)	1.17 (0.98, 1.41) 1.04 (0.86, 1.25) 1.07 (0.88, 1.29)	1.55 (1.29, 1.86) 1.16 (0.96, 1.40) 1.20 (0.99, 1.44)	1.63 (1.43, 1.85) 1.20 (1.05, 1.37) 1.22 (1.07, 1.40)	<0.0001 0.0061 0.0025
Lung (C34) in never smokers	Total n/cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	26095 / 29 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	81561 / 96 0.99 (0.66, 1.51) 1.00 (0.66, 1.53) 1.02 (0.67, 1.56)	75680 / 78 0.94 (0.61, 1.44) 0.94 (0.61, 1.47) 0.97 (0.62, 1.51)	75491 / 67 0.90 (0.58, 1.41) 0.89 (0.56, 1.41) 0.92 (0.58, 1.46)	258827 / 270 0.91 (0.65, 1.26) 0.89 (0.63, 1.25) 0.91 (0.65, 1.29)	0.5579 0.4969 0.6081
Malignant melanoma (C43)	Cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2 HR (95%-CI), Model 3	108 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	506 <b>1.35 (1.10, 1.67)</b> <b>1.24 (1.01, 1.53)</b> 1.22 (0.99, 1.50) 1.21 (0.98, 1.49)	499 <b>1.36 (1.10, 1.68)</b> 1.23 (0.99, 1.52) 1.20 (0.97, 1.49) 1.19 (0.96, 1.47)	492 <b>1.26 (1.02, 1.56)</b> 1.17 (0.94, 1.45) 1.14 (0.92, 1.41) 1.13 (0.91, 1.40)	1605 1.08 (0.94, 1.24) 1.04 (0.90, 1.20) 1.02 (0.89, 1.18) 1.02 (0.88, 1.18)	0.2872 0.5880 0.7539 0.8077
Breast (C50) †	Total n/cases HR (95%-Cl), Model 0 HR (95%-Cl), Model 1 HR (95%-Cl), Model 2	32197 / 630 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	96955 / 2156 <b>1.12 (1.02, 1.22)</b> 1.09 (1.00, 1.19) 1.06 (0.97, 1.16)	73137 / 1697 1.17 (1.07, 1.28) 1.14 (1.04, 1.25) 1.11 (1.01, 1.21)	52620 / 1183 1.15 (1.04, 1.27) 1.12 (1.01, 1.24) 1.07 (0.97, 1.19)	254909 / 5666 <b>1.11 (1.04, 1.20)</b> <b>1.09 (1.02, 1.18)</b> 1.06 (0.98, 1.14)	<b>0.0029</b> <b>0.0174</b> 0.1346
Endometrium (C54) †	Total n/cases HR (95%-Cl), Model 0 HR (95%-Cl), Model 1 HR (95%-Cl), Model 2	32197 / 85 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	96955 / 339 <b>1.29 (1.02, 1.64)</b> <b>1.40 (1.10, 1.79)</b> 1.27 (1.00, 1.62)	73137 / 262 <b>1.35 (1.06, 1.73)</b> <b>1.48 (1.15, 1.90)</b> 1.27 (0.99, 1.64)	52620 / 180 <b>1.34 (1.03, 1.73)</b> <b>1.45 (1.11, 1.89)</b> 1.19 (0.91, 1.55)	254909 / 866 <b>1.22 (1.01, 1.47)</b> <b>1.28 (1.06, 1.54)</b> 1.09 (0.90, 1.31)	<b>0.0349</b> <b>0.0101</b> 0.3835
Ovary (C56) †	Total n/cases HR (95%-Cl), Model 0 HR (95%-Cl), Model 1 HR (95%-Cl), Model 2	32197 / 73 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	96955 / 232 1.02 (0.79, 1.33) 1.06 (0.81, 1.38) 1.06 (0.81, 1.38)	73137 / 159 0.94 (0.71, 1.24) 0.99 (0.75, 1.32) 0.99 (0.74, 1.31)	52620 / 112 0.94 (0.70, 1.26) 0.99 (0.73, 1.34) 0.98 (0.73, 1.33)	254909 / 576 0.92 (0.74, 1.15) 0.97 (0.77, 1.21) 0.96 (0.77, 1.21)	0.4720 0.7638 0.7421
Prostate (C61) ‡	Total n/cases HR (95%-Cl), Model 0 HR (95%-Cl), Model 1 HR (95%-Cl), Model 2 HR (95%-Cl), Model 3	11849 / 276 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	46569 / 1374 1.11 (0.98, 1.27) 1.08 (0.94, 1.23) 1.09 (0.95, 1.24) 1.08 (0.95, 1.24)	64946 / 1868 1.11 (0.98, 1.27) 1.09 (0.95, 1.24) 1.10 (0.97, 1.25) 1.10 (0.97, 1.25)	94608 / 2424 1.06 (0.94, 1.21) 1.05 (0.93, 1.20) 1.07 (0.94, 1.22) 1.07 (0.94, 1.22)	217972 / 5942 0.99 (0.92, 1.06) 1.00 (0.93, 1.08) 1.01 (0.94, 1.10) 1.01 (0.94, 1.09)	0.7157 0.9868 0.7137 0.7415
Kidney (C64-65)	Cases HR (95%-Cl), Model 0 HR (95%-Cl), Model 1 HR (95%-Cl), Model 2	56 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	226 1.09 (0.81, 1.46) 1.07 (0.80, 1.44) 1.00 (0.75, 1.35)	220 1.00 (0.74, 1.34) 0.98 (0.72, 1.32) 0.89 (0.66, 1.21)	282 1.11 (0.83, 1.49) 1.07 (0.80, 1.45) 0.96 (0.71, 1.30)	784 1.07 (0.87, 1.31) 1.04 (0.84, 1.28) 0.96 (0.78, 1.18)	0.5196 0.7367 0.6779
Bladder (C67)	Cases HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	29 1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	162 1.40 (0.94, 2.08) 1.32 (0.88, 1.96) 1.29 (0.86, 1.92)	207 1.53 (1.03, 2.26) 1.38 (0.93, 2.05) 1.34 (0.90, 1.99)	234 1.42 (0.96, 2.10) 1.21 (0.81, 1.80) 1.16 (0.78, 1.73)	632 1.15 (0.92, 1.45) 1.00 (0.79, 1.27) 0.97 (0.77, 1.24)	0.2258 0.9828 0.8295
Lymphatic and hematopoietic	Cases	197	712	794	772	2475	

tissues (C81-96)							
	HR (95%-CI), Model 0	1.00 (Ref.)	1.01 (0.86, 1.18)	1.11 (0.95, 1.30)	0.98 (0.84, 1.15)	0.99 (0.88, 1.10)	0.7964
	HR (95%-CI), Model 1	1.00 (Ref.)	1.01 (0.86, 1.18)	1.11 (0.95, 1.31)	0.98 (0.84, 1.16)	0.98 (0.88, 1.10)	0.7854
	HR (95%-CI), Model 2	1.00 (Ref.)	1.01 (0.86, 1.18)	1.11 (0.94, 1.30)	0.98 (0.83, 1.15)	0.98 (0.87, 1.10)	0.7475
Non-Hodgkin lymphoma (C82-85)	Cases	92	338	385	374	1189	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.03 (0.82, 1.30)	1.18 (0.94, 1.49)	1.06 (0.84, 1.34)	1.06 (0.90, 1.24)	0.5086
	HR (95%-CI), Model 1	1.00 (Ref.)	1.04 (0.83, 1.32)	1.20 (0.95, 1.51)	1.07 (0.84, 1.36)	1.06 (0.89, 1.25)	0.5137
	HR (95%-CI), Model 2	1.00 (Ref.)	1.04 (0.82, 1.31)	1.19 (0.94, 1.50)	1.06 (0.84, 1.35)	1.05 (0.89, 1.24)	0.5599
Multiple myeloma (C90)	Cases	34	128	137	138	437	
Multiple myeloma (C90)	Cases HR (95%-CI), Model 0	34 1.00 (Ref.)	128 1.06 (0.73, 1.55)	137 1.13 (0.77, 1.65)	138 1.05 (0.72, 1.54)	437 1.03 (0.78, 1.34)	0.8536
Multiple myeloma (C90)		-	-	-		-	0.8536 0.6224
Multiple myeloma (C90)	HR (95%-CI), Model 0	1.00 (Ref.)	1.06 (0.73, 1.55)	1.13 (0.77, 1.65)	1.05 (0.72, 1.54)	1.03 (0.78, 1.34)	
Multiple myeloma (C90) Leukaemia (C91-C95)	HR (95%-CI), Model 0 HR (95%-CI), Model 1	1.00 (Ref.) 1.00 (Ref.)	1.06 (0.73, 1.55) 1.08 (0.74, 1.59)	1.13 (0.77, 1.65) 1.18 (0.80, 1.74)	1.05 (0.72, 1.54) 1.11 (0.75, 1.64)	1.03 (0.78, 1.34) 1.07 (0.81, 1.41)	0.6224
	HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2	1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.)	1.06 (0.73, 1.55) 1.08 (0.74, 1.59) 1.08 (0.74, 1.59)	1.13 (0.77, 1.65) 1.18 (0.80, 1.74) 1.18 (0.80, 1.74)	1.05 (0.72, 1.54) 1.11 (0.75, 1.64) 1.10 (0.74, 1.63)	1.03 (0.78, 1.34) 1.07 (0.81, 1.41) 1.06 (0.81, 1.40)	0.6224
	HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2 Cases	1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 59	1.06 (0.73, 1.55) 1.08 (0.74, 1.59) 1.08 (0.74, 1.59) 214	1.13 (0.77, 1.65) 1.18 (0.80, 1.74) 1.18 (0.80, 1.74) 227	1.05 (0.72, 1.54) 1.11 (0.75, 1.64) 1.10 (0.74, 1.63) 221	1.03 (0.78, 1.34) 1.07 (0.81, 1.41) 1.06 (0.81, 1.40) 721	0.6224 0.6574
	HR (95%-CI), Model 0 HR (95%-CI), Model 1 HR (95%-CI), Model 2 Cases HR (95%-CI), Model 0	1.00 (Ref.) 1.00 (Ref.) 1.00 (Ref.) 59 1.00 (Ref.)	1.06 (0.73, 1.55) 1.08 (0.74, 1.59) 1.08 (0.74, 1.59) 214 0.98 (0.74, 1.31)	1.13 (0.77, 1.65) 1.18 (0.80, 1.74) 1.18 (0.80, 1.74) 227 0.99 (0.74, 1.32)	1.05 (0.72, 1.54) 1.11 (0.75, 1.64) 1.10 (0.74, 1.63) 221 0.86 (0.64, 1.15)	1.03 (0.78, 1.34) 1.07 (0.81, 1.41) 1.06 (0.81, 1.40) 721 0.86 (0.70, 1.06)	0.6224 0.6574 0.1677

Bold where p <0.05. CI, Confidence interval; HR, Hazard ratio; LR, likelihood ratio test.

Model 0: Stratified for sex, age group and region and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown).

Model 1: Model 0 + deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current  $\geq$ 15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents,  $\geq$ 50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day,  $\geq$ 20 g/day, unknown), total fruit and vegetable intake (< 3 servings/day, 3-< 4 servings/day, 4-< 6 servings/day,  $\geq$ 6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2,  $\geq$ 3, unknown), hormone-replacement therapy use (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown). Model 2: Model 1 + body mass index (sex-specific quintiles, unknown).

Model 3: For malignant melanoma: Model 2 + skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black, other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year, ≥3 times/year, unknown); for prostate cancer: Model 2 + enlarged prostate (yes, no, unknown).

\* In 22 cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

† Analyses restricted to women.

‡ Analyses restricted to men.

Site (ICD-10)	Model	Model Poultry intake (times/week), (mean g/day)								
		<1 (12.2)	1-<2 (27.4)	≥2 (39.4)	per 30 g higher intake	Ptrend				
	Total n	75015	169479	228554	473048					
Dral (C00-C14)	Cases	103	193	262	558					
	HR (95%-CI), Model 0	1.00 (Ref.)	0.79 (0.63, 1.01)	0.84 (0.67, 1.05)	0.85 (0.66, 1.10)	0.2263				
	HR (95%-CI), Model 1	1.00 (Ref.)	0.86 (0.67, 1.09)	0.96 (0.76, 1.21)	0.99 (0.77, 1.28)	0.9419				
	HR (95%-CI), Model 2	1.00 (Ref.)	0.87 (0.68, 1.11)	0.98 (0.78, 1.24)	1.02 (0.79, 1.32)	0.8955				
Desophagus (C15)	Cases	79	221	233	533					
	HR (95%-CI), Model 0	1.00 (Ref.)	1.16 (0.89, 1.50)	1.06 (0.82, 1.37)	1.02 (0.78, 1.33)	0.8765				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.25 (0.96, 1.62)	1.19 (0.92, 1.54)	1.15 (0.88, 1.51)	0.3008				
	HR (95%-CI), Model 2	1.00 (Ref.)	1.23 (0.95, 1.60)	1.16 (0.89, 1.50)	1.12 (0.86, 1.47)	0.4092				
Stomach (C16)	Cases	60	130	166	356					
	HR (95%-CI), Model 0	1.00 (Ref.)	0.89 (0.65, 1.21)	0.98 (0.73, 1.32)	1.02 (0.73, 1.41)	0.9138				
	HR (95%-CI), Model 1	1.00 (Ref.)	0.95 (0.69, 1.29)	1.07 (0.79, 1.45)	1.11 (0.80, 1.55)	0.5180				
	HR (95%-CI), Model 2	1.00 (Ref.)	0.94 (0.69, 1.27)	1.05 (0.78, 1.42)	1.09 (0.78, 1.52)	0.6074				
Colorectum (C18-20)*	Cases	485	1274	1467	3226	0.0001				
	HR (95%-CI), Model 0	1.00 (Ref.)	1.11 (1.00, 1.23)	1.07 (0.96, 1.18)	1.05 (0.94, 1.17)	0.3923				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.09 (0.98, 1.21)	1.05 (0.95, 1.16)	1.03 (0.92, 1.15)	0.5858				
	HR (95%-CI), Model 2	1.00 (Ref.)	1.08 (0.97, 1.20)	1.03 (0.93, 1.15)	1.01 (0.91, 1.13)	0.8256				
colon (C18)	Cases	328	829	976	2133	0.0200				
	HR (95%-CI), Model 0	1.00 (Ref.)	1.06 (0.93, 1.21)	1.05 (0.92, 1.19)	1.04 (0.91, 1.19)	0.5686				
						0.5666				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.04 (0.92, 1.19)	1.03 (0.91, 1.17)	1.02 (0.89, 1.17)					
(010.00)	HR (95%-CI), Model 2	1.00 (Ref.)	1.03 (0.90, 1.17)	1.00 (0.88, 1.14)	0.99 (0.87, 1.14)	0.9238				
lectum (C19-20)		162	455	498	1115	0.0075				
	HR (95%-CI), Model 0	1.00 (Ref.)	1.19 (0.99, 1.42)	1.09 (0.91, 1.30)	1.05 (0.87, 1.26)	0.6275				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.17 (0.97, 1.40)	1.07 (0.90, 1.29)	1.03 (0.86, 1.25)	0.7341				
	HR (95%-CI), Model 2	1.00 (Ref.)	1.17 (0.97, 1.40)	1.07 (0.90, 1.29)	1.03 (0.86, 1.24)	0.7441				
iver (C22)	Cases	55	109	139	303					
	HR (95%-CI), Model 0	1.00 (Ref.)	0.83 (0.60, 1.15)	0.89 (0.65, 1.22)	0.92 (0.65, 1.30)	0.6191				
	HR (95%-CI), Model 1	1.00 (Ref.)	0.92 (0.66, 1.28)	1.01 (0.74, 1.39)	1.04 (0.73, 1.48)	0.8204				
	HR (95%-CI), Model 2	1.00 (Ref.)	0.91 (0.66, 1.27)	0.99 (0.72, 1.36)	1.01 (0.71, 1.44)	0.9461				
ancreas (C25)	Cases	105	244	257	606					
	HR (95%-CI), Model 0	1.00 (Ref.)	0.98 (0.78, 1.23)	0.88 (0.70, 1.11)	0.86 (0.67, 1.09)	0.2113				
	HR (95%-CI), Model 1	1.00 (Ref.)	1.01 (0.80, 1.28)	0.93 (0.74, 1.18)	0.91 (0.71, 1.17)	0.4727				
	HR (95%-CI), Model 2	1.00 (Ref.)	1.00 (0.79, 1.26)	0.91 (0.72, 1.15)	0.89 (0.69, 1.14)	0.3503				
ung (C34)	Cases	410	800	855	2065					
0	HR (95%-CI), Model 0	1.00 (Ref.)	0.81 (0.72, 0.92)	0.74 (0.66, 0.83)	0.72 (0.64, 0.82)	<0.0001				
	HR (95%-CI), Model 1	1.00 (Ref.)	0.92 (0.81, 1.03)	0.92 (0.82, 1.04)	0.93 (0.81, 1.06)	0.2536				
	HR (95%-CI), Model 2	1.00 (Ref.)	0.92 (0.82, 1.04)	0.94 (0.83, 1.06)	0.94 (0.83, 1.08)	0.3940				
ung (C34) in never smokers	Total n/cases	39774 / 46	91572 / 88	127694 / 136	259040 / 270	-				
	HR (95%-CI), Model 0	1.00 (Ref.)	0.80 (0.56, 1.15)	1.03 (0.74, 1.45)	1.13 (0.78, 1.66)	0.5129				
	HR (95%-CI), Model 1	1.00 (Ref.)	0.82 (0.57, 1.17)	1.07 (0.76, 1.50)	1.18 (0.80, 1.73)	0.4021				
	HR (95%-CI), Model 2	1.00 (Ref.)	0.83 (0.58, 1.19)	1.09 (0.78, 1.54)	1.21 (0.82, 1.78)	0.3321				

S8 Table. Hazard ratios and 95% confidence intervals of cancer incidence by site according to poultry intake in UK Biobank

Malignant melanoma (C43)	Cases	229	594	785	1608	
	HR (95%-CI), Model 0	1.00 (Ref.)	1.12 (0.96, 1.30)	1.19 (1.02, 1.38)	1.20 (1.03, 1.40)	0.0209
	HR (95%-CI), Model 1	1.00 (Ref.)	1.04 (0.89, 1.22)	1.10 (0.95, 1.28)	1.12 (0.96, 1.31)	0.1588
	HR (95%-CI), Model 2	1.00 (Ref.)	1.03 (0.89, 1.20)	1.09 (0.93, 1.26)	1.10 (0.94, 1.29)	0.2281
	HR (95%-CI), Model 3	1.00 (Ref.)	1.02 (0.88, 1.19)	1.06 (0.91, 1.24)	1.08 (0.92, 1.26)	0.3657
Breast (C50) †	Total n/cases	41883 / 900	88925 / 2031	124256 / 2745	255064 / 5676	
2.000 (000)	HR (95%-CI), Model 0	1.00 (Ref.)	1.04 (0.96, 1.12)	1.04 (0.96, 1.12)	1.03 (0.95, 1.12)	0.4225
	HR (95%-CI), Model 1	1.00 (Ref.)	1.04 (0.96, 1.12)	1.05 (0.97, 1.13)	1.05 (0.97, 1.14)	0.2410
	HR (95%-CI), Model 2	1.00 (Ref.)	1.02 (0.94, 1.10)	1.02 (0.94, 1.10)	1.02 (0.94, 1.10)	0.7059
Endometrium (C54) †	Total n/cases	41883 / 144	88925 / 296	124256 / 428	255064 / 868	
	HR (95%-CI), Model 0	1.00 (Ref.)	0.93 (0.76, 1.13)	1.04 (0.86, 1.25)	1.08 (0.88, 1.33)	0.4777
	HR (95%-CI), Model 1	1.00 (Ref.)	1.00 (0.82, 1.22)	1.15 (0.95, 1.40)	1.21 (0.98, 1.49)	0.0770
	HR (95%-CI), Model 2	1.00 (Ref.)	0.94 (0.77, 1.15)	1.02 (0.84, 1.23)	1.05 (0.85, 1.29)	0.6682
Ovary (C56) †	Total n/cases	41883 / 97	88925 / 201	124256 / 281	255064 / 579	0.0001
	HR (95%-CI), Model 0	1.00 (Ref.)	0.93 (0.73, 1.19)	1.00 (0.79, 1.26)	1.02 (0.79, 1.31)	0.8865
	HR (95%-CI), Model 1	1.00 (Ref.)	0.98 (0.77, 1.25)	1.06 (0.84, 1.34)	1.08 (0.84, 1.40)	0.5369
	HR (95%-CI), Model 2	1.00 (Ref.)	0.98 (0.77, 1.25)	1.05 (0.83, 1.33)	1.08 (0.84, 1.39)	0.5587
Prostate (C61) ‡	Total n/cases	33132 / 873	80554 / 2440	104298 / 2633	217984 / 5946	0.0007
	HR (95%-CI), Model 0	1.00 (Ref.)	<b>1.14 (1.05, 1.23)</b>	<b>1.12 (1.04, 1.21)</b>	1.10 (1.02, 1.19)	0.0179
	HR (95%-CI), Model 1	1.00 (Ref.)	1.11 (1.03, 1.20)	1.08 (1.00, 1.16)	1.06 (0.98, 1.15)	0.1739
	HR (95%-CI), Model 2	1.00 (Ref.)	1.11 (1.03, 1.20)	<b>1.09 (1.00, 1.17)</b>	1.07 (0.98, 1.16)	0.1759
	HR (95%-CI), Model 2 HR (95%-CI), Model 3	1.00 (Ref.)	1.11 (1.03, 1.20)	1.08 (1.00, 1.17)	1.07 (0.98, 1.16)	0.1132
Kidney (C64-65)	Cases	135	287	361	783	0.1202
Kidney (C64-65)	HR (95%-CI), Model 0	1.00 (Ref.)	0.89 (0.72, 1.09)	0.94 (0.77, 1.15)	0.97 (0.78, 1.20)	0.7547
	HR (95%-CI), Model 0 HR (95%-CI), Model 1	1.00 (Ref.)	0.89 (0.72, 1.09)	0.94 (0.77, 1.15)	1.01 (0.81, 1.26)	0.7547
	HR (95%-CI), Model 2	1.00 (Ref.)	0.88 (0.71, 1.08)	0.98 (0.80, 1.20) 0.93 (0.76, 1.13)	0.95 (0.76, 1.18)	0.6334
Diaddar (CCZ)	· · · ·					0.0334
Bladder (C67)	Cases	119 1.00 (Ref.)	230 0.80 (0.64, 0.99)	283	632 0.91 (0.71, 1.16)	0.4305
	HR (95%-CI), Model 0 HR (95%-CI), Model 1	1.00 (Ref.)	,	0.88 (0.71, 1.09) 0.94 (0.75, 1.16)	0.91 (0.71, 1.16)	0.4305
	HR (95%-CI), Model 2	( )	0.82 (0.65, 1.02) 0.81 (0.65, 1.02)	0.94 (0.75, 1.16)	0.98 (0.76, 1.25)	0.8429
Lymphotic and benetopointic	HR (95%-CI), MOUEI 2	1.00 (Ref.)	0.81 (0.85, 1.02)	0.92 (0.74, 1.14)	0.95 (0.75, 1.22)	0.7125
Lymphatic and hematopoietic	<b>C</b>	255	070	1110	0474	
tissues (C81-96)	Cases	355	970	1149	2474	0.0460
	HR (95%-CI), Model 0	1.00 (Ref.)	1.16 (1.02, 1.31)	1.15 (1.02, 1.30) 1.18 (1.05, 1.33)	1.13 (1.00, 1.29) 1.17 (1.03, 1.32)	0.0469 0.0175
	HR (95%-CI), Model 1 HR (95%-CI), Model 2	1.00 (Ref.)	1.18 (1.04, 1.33)		,	0.0175
New Heddelin knowkerse (000.05)		1.00 (Ref.)	1.18 (1.04, 1.33)	1.18 (1.04, 1.33)	1.16 (1.03, 1.32)	0.0100
Non-Hodgkin lymphoma (C82-85)		169	465	553	1187	0.4.400
	HR (95%-CI), Model 0	1.00 (Ref.)	1.17 (0.98, 1.39)	1.16 (0.98, 1.38)	1.14 (0.95, 1.37)	0.1496
	HR (95%-CI), Model 1	1.00 (Ref.)	1.19 (1.00, 1.42)	1.19 (1.00, 1.42)	1.18 (0.98, 1.41)	0.0797
	HR (95%-CI), Model 2	1.00 (Ref.)	1.19 (0.99, 1.42)	1.19 (1.00, 1.42)	1.17 (0.98, 1.41)	0.0905
Multiple myeloma (C90)		62	177	197	436	0 550 4
	HR (95%-CI), Model 0	1.00 (Ref.)	1.21 (0.91, 1.62)	1.14 (0.85, 1.51)	1.09 (0.81, 1.47)	0.5534
	HR (95%-CI), Model 1	1.00 (Ref.)	1.23 (0.92, 1.65)	1.14 (0.86, 1.53)	1.09 (0.81, 1.47)	0.5555
	HR (95%-CI), Model 2	1.00 (Ref.)	1.23 (0.92, 1.65)	1.14 (0.85, 1.52)	1.09 (0.81, 1.47)	0.5696
Leukaemia (C91-C95)	Cases	109	288	326	723	

HR (95%-CI), Model 0	1.00 (Ref.)	1.11 (0.89, 1.38)	1.07 (0.86, 1.33)	1.05 (0.83, 1.32)	0.6802
HR (95%-CI), Model 1	1.00 (Ref.)	1.12 (0.89, 1.39)	1.09 (0.88, 1.36)	1.08 (0.85, 1.36)	0.5293
HR (95%-CI), Model 2	1.00 (Ref.)	1.12 (0.89, 1.40)	1.10 (0.88, 1.37)	1.08 (0.86, 1.37)	0.5059

Bold where p <0.05. CI, Confidence interval; HR, Hazard ratio; LR, likelihood ratio test.

Model 0: Stratified for sex, age group and region and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown).

Model 1: Model 0 + deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current  $\geq$ 15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents,  $\geq$ 50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day,  $\geq$ 20 g/day, unknown), total fruit and vegetable intake (< 3 servings/day, 3-< 4 servings/day, 4-< 6 servings/day,  $\geq$ 6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2,  $\geq$ 3, unknown), hormone-replacement therapy use (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown). Model 2: Model 1 + body mass index (sex-specific quintiles, unknown).

Model 3: For malignant melanoma: Model 2 + skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black,

other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year, ≥3 times/year, unknown); for prostate cancer: Model 2 + enlarged prostate (yes, no, unknown).

\* In 22 cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

† Analyses restricted to women.

‡ Analyses restricted to men.

		Women		Men		
Meat type (increment)		per increment higher intake	P <sub>trend</sub>	per increment higher intake	P <sub>trend</sub>	LR test for interaction
Total meat intake						
(100 g)	Total n	252268		215152		
Colorectum (C18-20)	Cases	1342		1852		
	HR (95%-CI)	1.15 (0.92, 1.44)	0.2087	1.46 (1.16, 1.85)	0.0013	0.0196
Colon (C18)	Cases	985	0.0004	1126		0.0744
De ature (010.00)	HR (95%-CI)	1.29 (0.99, 1.67)	0.0601	1.31 (0.98, 1.76)	0.0707	0.3711
Rectum (C19-20)		369	0 4960	736	0.0077	0.0059
	HR (95%-CI)	0.87 (0.58, 1.30)	0.4869	1.67 (1.14, 2.43)	0.0077	0.0059
Red and processed						
meat intake (70 g)	Total n	252422		215355		
Colorectum (C18-20)	Cases	1345		1855		
	HR (95%-CI)	1.16 (0.95, 1.42)	0.1480	1.51 (1.22, 1.86)	0.0001	0.0073
Colon (C18)	Cases	987		1127		
	HR (95%-CI)	1.26 (0.99, 1.60)	0.0569	1.59 (1.21, 2.09)	0.0009	0.0404
Rectum (C19-20)	Cases	370		738		
	HR (95%-CI)	0.91 (0.63, 1.32)	0.6232	1.41 (1.01, 1.95)	0.0417	0.0285
Red meat intake (50 g)	Total n	252745		215619		
Colorectum (C18-20)	Cases	1345		1856		
	HR (95%-CI)	1.09 (0.88, 1.34)	0.4425	1.38 (1.11, 1.70)	0.0031	0.0160
Colon (C18)	Cases	987		1127		
	HR (95%-CI)	1.16 (0.91, 1.49)	0.2395	1.61 (1.22, 2.13)	0.0008	0.0196
Rectum (C19-20)	Cases	370		739		
	HR (95%-CI)	0.88 (0.60, 1.30)	0.5241	1.11 (0.80, 1.53)	0.5409	0.1962
Processed meat intake						
(20 g)	Total n	254909		217972		
Colorectum (C18-20)	Cases	1356		1872		
	HR (95%-CI)	1.10 (0.94, 1.28)	0.2295	1.26 (1.09, 1.45)	0.0021	0.0371
Colon (C18)	Cases	993		1141		
	HR (95%-CI)	1.07 (0.90, 1.28)	0.4338	1.21 (1.00, 1.45)	0.0477	0.1232
Rectum (C19-20)	Cases HR (95%-CI)	375	0.0005	741		0.4.400
	HK (95%-CI)	1.14 (0.85, 1.52)	0.3835	1.35 (1.07, 1.71)	0.0104	0.1480
Poultry intake (30 g)	Total n	255064		217984		
Colorectum (C18-20)	Cases	1355		1871		
, , ,	HR (95%-CI)	0.91 (0.77, 1.07)	0.2456	1.12 (0.96, 1.30)	0.1394	0.0216
Colon (C18)	Cases	<b>`993</b> ´´´		1140		
	HR (95%-CI)	0.98 (0.80, 1.19)	0.8316	1.02 (0.85, 1.23)	0.8309	0.4305
Rectum (C19-20)	Cases	374		741		
	HR (95%-CI)	0.73 (0.54, 0.99)	0.0455	1.27 (1.00, 1.61)	0.0487	0.0033


S9 Table. Multivariable adjusted hazard ratios and 95% confidence intervals of colorectal, colon and rectal cancer incidence by meat type and sex in UK Biobank\*

Bold where p <0.05. CI, Confidence interval; HR, Hazard ratio; LR, likelihood ratio test.

\*Hazard ratios stratified for age group and region and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown), deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sexspecific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current ≥15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents, ≥50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day, ≥20 g/day, unknown), total fruit and vegetable intake (<3 servings/day, 3-<4 servings/day, 4-<6 servings/day, ≥6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2, ≥3, unknown), hormone-replacement therapy (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown), body mass index (sex-specific quintiles, unknown).

## Supplementary figures

(	A) cases	I	HR (95% Cl) per 100g/day	(B) cases	1	HR (95% Cl) per 100g/day
Oral (C00-C14)	423		1.05 (0.69, 1.59)	183		1.11 (0.60, 2.05)
Oesophagus (C15)	405			162 —	<b>e</b>	0.85 (0.45, 1.62)
Stomach (C16)	264		■	130		→ 1.38 (0.64, 2.94)
Colorectum (C18-20)†	2390	_ <b></b>	1.30 (1.08, 1.56)	1465	<b>_</b>	1.32 (1.05, 1.66)
Colon (C18)	1591	<b>_</b>	1.29 (1.03, 1.61)	998	<b>_</b>	1.14 (0.87, 1.49)
Rectum (C19-20)	812		1.28 (0.93, 1.75)	475		■ → 1.84 (1.20, 2.81)
Liver (C22)	241		1.27 (0.72, 2.25)	107 <		0.67 (0.31, 1.45)
Pancreas (C25)	480		1.08 (0.73, 1.61)	267		— 1.13 (0.67, 1.90)
Lung (C34)	1593	<b>_</b>	1.28 (1.03, 1.60)	261		1.02 (0.61, 1.69)
in never smokers ‡	201		1.00 (0.56, 1.77)			
Malignant melanoma (C43) §	1206		0.98 (0.76, 1.26)	918	<b>=</b>	1.04 (0.78, 1.37)
Breast (C50) ¶	4119	_ <b></b>	1.06 (0.93, 1.20)	3266	_ <b>_</b>	1.03 (0.90, 1.19)
Endometrium (C54) ¶	644		0.96 (0.70, 1.31)	557		1.14 (0.81, 1.60)
Ovary (C56) ¶	416	<b>e</b>	0.77 (0.53, 1.11)	333		0.96 (0.63, 1.47)
Prostate (C61) \\	4463	<b>⊢</b> ∎	1.13 (0.98, 1.30)	2777	_ <b>_</b>	1.03 (0.87, 1.22)
Kidney (C64-65)	614		1.02 (0.72, 1.46)	326		0.97 (0.60, 1.56)
Bladder (C67)	456		0.85 (0.56, 1.29)	183		1.19 (0.62, 2.28)
Lymphatic and hematopoietic tissues (C81-96	6) 1869	_ <b></b>	1.09 (0.89, 1.33)	1210		1.04 (0.82, 1.33)
Non-Hodgkin Lymphoma (C82-85)	896		1.27 (0.94, 1.70)	605		1.05 (0.75, 1.47)
Multiple Myeloma (C90)	341		0.85 (0.55, 1.33)	213		→ 1.46 (0.80, 2.64)
Leukaemia (C91-C95)	547		0.88 (0.61, 1.26)	333 —		0.74 (0.48, 1.16)
	0.	5 0.75 1 1.5	2	0.5	6 0.75 1 1.5	2



CI, Confidence interval; HR, Hazard ratio.

\* Stratified for sex, age group (<45, 45-<50, 50-<55, 55-<60, 60-<65 and ≥65 years) and region (London, Wales, North-West, North-East, Yorkshire and Humber, West Midlands, East Midlands, South-East, South-West, Scotland) and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown), deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current ≥15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents, ≥50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day, ≥20 g/day, unknown), total fruit and vegetable intake (<3 servings/day, 3-<4 servings/day, 4-<6 servings/day, ≥6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), body mass index (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2, ≥3, unknown), hormone-replacement therapy (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown).

† In 13 (A) and 8 (B) cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

 $\ddagger$  Analyses restricted to never smokers (A: n = 252,436).

§ Additionally adjusted for skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black, other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year,  $\geq$ 3 times/year, unknown).

¶ Analyses restricted to women (A: n = 248,520; B: n = 150,480).

 $\land$  Analyses restricted to men (A: n = 210,843; B: n = 105,529).

(/	A)			(B)		
	cases	Ĩ	HR (95% CI) per 70g/day	cases	Т	HR (95% Cl) per 70g/day
Oral (C00-C14)	423		0.95 (0.65, 1.38)	183		0.70 (0.41, 1.18)
	425		1.23 (0.81, 1.87)	163	-	- 1.01 (0.55, 1.85)
Oesophagus (C15)	264	-			_	
Stomach (C16)				130		→ 1.31 (0.66, 2.59)
Colorectum (C18-20)†	2395		1.34 (1.14, 1.59)	1468		- 1.50 (1.22, 1.85)
Colon (C18)	1593		1.37 (1.12, 1.68)	999		1.35 (1.05, 1.74)
Rectum (C19-20)	815		1.26 (0.94, 1.68)	477		→ 1.79 (1.22, 2.61)
Liver (C22)	241		0.98 (0.60, 1.62)	107 ←		0.74 (0.36, 1.52)
Pancreas (C25)	482		1.19 (0.82, 1.72)	268		1.02 (0.64, 1.63)
Lung (C34)	1595		1.39 (1.13, 1.72)	261		0.88 (0.56, 1.38)
in never smokers ‡	201 -		0.85 (0.51, 1.43)			
Malignant melanoma (C43) §	1206		1.05 (0.84, 1.32)	918		1.10 (0.85, 1.43)
Breast (C50) ¶	4121		1.04 (0.93, 1.17)	3267	+	1.10 (0.97, 1.25)
Endometrium (C54) ¶	645		0.92 (0.69, 1.22)	558		1.06 (0.78, 1.45)
Ovary (C56) ¶	416		0.75 (0.53, 1.05)	333		0.77 (0.52, 1.12)
Prostate (C61) \\	4464		1.14 (1.00, 1.29)	2777		1.02 (0.88, 1.19)
Kidney (C64-65)	615		1.01 (0.73, 1.40)	327	<b>e</b>	1.02 (0.66, 1.58)
Bladder (C67)	456		0.95 (0.64, 1.40)	183		1.33 (0.73, 2.42)
Lymphatic and hematopoietic tissues (C81-96	) 1871		0.96 (0.80, 1.15)	1210		0.87 (0.70, 1.08)
Non-Hodgkin Lymphoma (C82-85)	897		1.11 (0.85, 1.44)	605		0.94 (0.69, 1.27)
Multiple Myeloma (C90)	342		0.90 (0.60, 1.36)	213		0.89 (0.54, 1.47)
Leukaemia (C91-C95)	547		0.75 (0.54, 1.05)	333 -		0.72 (0.48, 1.08)
S2 Fig. Associations of red and pro	0.9		2	( 0		2

S2 Fig. Associations of <u>red and processed meat</u> intake and cancer incidence by cancer site (per 70g/day) when excluding first 2 years of follow-up (A, n = 459,713) and including only never smokers (B, n = 256,182)\*

CI, Confidence interval; HR, Hazard ratio.

\* Stratified for sex, age group (<45, 45-<50, 50-<55, 55-<60, 60-<65 and ≥65 years) and region (London, Wales, North-West, North-East, Yorkshire and Humber, West Midlands, East Midlands, South-East, South-West, Scotland) and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown), deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current ≥15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents, ≥50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day, ≥20 g/day, unknown), total fruit and vegetable intake (<3 servings/day, 3-<4 servings/day, 4-<6 servings/day, ≥6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), body mass index (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2, ≥3, unknown), hormone-replacement therapy (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown).

+ In 13 (A) and 8 (B) cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

‡ Analyses restricted to never smokers (A: n = 252,608).

§ Additionally adjusted for skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black, other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year, ≥3 times/year, unknown).

 $\P$  Analyses restricted to women (A: n = 248,673; B: n = 150,571).

 $\Lambda$  Analyses restricted to men (A: n = 211,040; B: n = 105,611).

(B)	(A)
HR (95% CI) per 50g/day cases HR (95% CI) per 50g/day	cases
<b>—</b> 0.95 (0.65, 1.39) 183 <b>—</b> 0.86 (0.49, 1.51)	00-C14) 423
<b>■</b> 1.22 (0.80, 1.86) 163 <b>■</b> 1.04 (0.56, 1.95)	nagus (C15) 406
<b>→</b> 1.41 (0.83, 2.38) 130 <b>→</b> 1.68 (0.81, 3.49)	ch (C16) 266
1.22 (1.03, 1.45) 1469 1.45 (1.17, 1.80)	ctum (C18-20)† 2396
<u>−−−</u> 1.29 (1.04, 1.59) 999 <u>−−−</u> 1.38 (1.06, 1.80)	lon (C18) 1593
<u>−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−−</u>	ctum (C19-20) 816
■ 1.09 (0.65, 1.83) 109  ■ 0.75 (0.36, 1.55)	242
<b>1.21 (0.82, 1.77) 268 1.00 (0.61, 1.64)</b>	as (C25) 482
1.28 (1.04, 1.58) 262 <u></u> 0.95 (0.58, 1.53)	234) 1598
0.90 (0.52, 1.55)	never smokers ‡ 202
<u> </u>	ant melanoma (C43) § 1208
<b>■</b> 1.10 (0.97, 1.23) 3275 <b>■</b> 1.17 (1.02, 1.34)	(C50) ¶ 4128
<b>.</b> 0.96 (0.71, 1.29) 558 <b>.</b> 1.20 (0.86, 1.66)	etrium (C54) ¶ 645
■ 0.75 (0.52, 1.07) 333 ■ 0.63 (0.43, 0.94)	(C56) ¶ 418
<b>─</b> 1.22 (1.07, 1.40) 2778 <b>1</b> .16 (0.98, 1.36)	e (C61) \\ 4472
0.97 (0.70, 1.36) 327 <b></b> 0.86 (0.55, 1.35)	(C64-65) 615
<u> </u>	r (C67) 458
	atic and hematopoietic tissues (C81-96) 1873
■ 1.19 (0.90, 1.56) 606 ■ 1.08 (0.78, 1.49)	n-Hodgkin Lymphoma (C82-85) 898
<b>0.86 (0.56, 1.32) 213 0.85 (0.50, 1.45)</b>	Itiple Myeloma (C90) 342
<b>.</b> 0.77 (0.55, 1.09) 334 <b>.</b> 0.75 (0.49, 1.16)	ukaemia (C91-C95) 548
0.75 1 1.5 2 0.55, 1.09) 334 0.5 0.75 1 1.5 0.75 1 1.5 2 0.5 0.75 1 1.5	

S3 Fig. Associations of <u>red meat intake</u> and cancer incidence by cancer site (per 50g/day) when excluding first 2 years of follow-up (A, n = 460,288) and including only never smokers (B, n = 256,545)\*

CI, Confidence interval; HR, Hazard ratio.

\* Stratified for sex, age group (<45, 45-<50, 50-<55, 55-<60, 60-<65 and ≥65 years) and region (London, Wales, North-West, North-East, Yorkshire and Humber, West Midlands, East Midlands, South-East, South-West, Scotland) and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown), deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current ≥15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents, ≥50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day, ≥20 g/day, unknown), total fruit and vegetable intake (<3 servings/day, 3-<4 servings/day, 4-<6 servings/day, ≥6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), body mass index (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2, ≥3, unknown), hormone-replacement therapy (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown).

+ In 13 (A) and 8 (B) cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

‡ Analyses restricted to never smokers (A: n = 252,965).

§ Additionally adjusted for skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black, other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year,  $\geq$ 3 times/year, unknown). ¶ Analyses restricted to women (A: n = 248,991; B: n = 150,793).

 $\land$  Analyses restricted to men (A: n = 211,297; B: n = 105,572).

(,	A) cases		HR (95% Cl) per 20g/day	(B) cases		HR (95% Cl) per 20g/day
	00000		···· (•• // •·/ ••· =•9/44/	Cucco	1	
Oral (C00-C14)	430		0.91 (0.69, 1.21)	185 -	<b>_</b>	0.72 (0.48, 1.07)
Oesophagus (C15)	412		1.10 (0.82, 1.48)	164	<b>e</b>	0.91 (0.58, 1.42)
Stomach (C16)	268	<b>_</b>	1.19 (0.83, 1.71)	131		- 1.10 (0.67, 1.81)
Colorectum (C18-20)†	2419		1.22 (1.08, 1.37)	1479	<b>_</b>	1.16 (1.00, 1.35)
Colon (C18)	1611		1.17 (1.01, 1.35)	1007	_ <b>_</b>	1.01 (0.84, 1.21)
Rectum (C19-20)	821	·	1.31 (1.06, 1.61)	480		1.54 (1.17, 2.02)
Liver (C22)	244		1.12 (0.77, 1.62)	108		- 1.00 (0.57, 1.73)
Pancreas (C25)	486		1.05 (0.80, 1.37)	268		0.97 (0.69, 1.38)
Lung (C34)	1632	_ <b>_</b>	1.21 (1.04, 1.40)	270		0.91 (0.65, 1.29)
in never smokers ‡	210		0.96 (0.65, 1.41)			
Malignant melanoma (C43) §	1210		0.99 (0.84, 1.17)	920		0.87 (0.72, 1.05)
Breast (C50) ¶	4168		1.04 (0.95, 1.13)	3301		1.04 (0.94, 1.14)
Endometrium (C54) ¶	653	<b>e</b>	1.01 (0.81, 1.26)	567		1.09 (0.87, 1.38)
Ovary (C56) ¶	419		0.90 (0.69, 1.18)	334		0.94 (0.70, 1.28)
Prostate (C61) \\	4519		1.06 (0.97, 1.15)	2807		0.98 (0.88, 1.10)
Kidney (C64-65)	621		0.91 (0.72, 1.15)	332		1.05 (0.76, 1.45)
Bladder (C67)	464		0.89 (0.67, 1.17)	184		1.35 (0.88, 2.09)
Lymphatic and hematopoietic tissues (C81-96	) 1891		0.99 (0.86, 1.13)	1221	_ <b>_</b>	0.97 (0.83, 1.14)
Non-Hodgkin Lymphoma (C82-85)	904	<b>_</b>	1.10 (0.91, 1.34)	609	<b>_</b>	1.03 (0.82, 1.29)
Multiple Myeloma (C90)	346		1.06 (0.78, 1.44)	218		1.15 (0.78, 1.69)
Leukaemia (C91-C95)	555		0.81 (0.64, 1.04)	334		0.82 (0.60, 1.12)
S4 Fig. Associations of processed	0.		2 2		.5 0.75 1 1.5	2

# S4 Fig. Associations of <u>processed meat</u> intake and cancer incidence by cancer site (per 20g/day) when excluding first 2 years of follow-up (A, n = 464,736) and including only never smokers (B, n = 258,827)\*

#### CI, Confidence interval; HR, Hazard ratio.

\* Stratified for sex, age group (<45, 45-<50, 50-<55, 55-<60, 60-<65 and ≥65 years) and region (London, Wales, North-West, North-East, Yorkshire and Humber, West Midlands, East Midlands, South-East, South-West, Scotland) and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown), deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current ≥15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents, ≥50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day, ≥20 g/day, unknown), total fruit and vegetable intake (<3 servings/day, 3-<4 servings/day, 4-<6 servings/day, ≥6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), body mass index (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2, ≥3, unknown), hormone-replacement therapy (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown).

+ In 13 (A) and 8 (B) cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

‡ Analyses restricted to never smokers (A: n = 255,227).

§ Additionally adjusted for skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black, other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year,  $\geq$ 3 times/year, unknown). ¶ Analyses restricted to women (A: n = 251,120; B: n = 152,058).

 $\land$  Analyses restricted to men (A: n = 213,616; B: n = 106,769).

(	A) cases		HR (95% Cl) per 30g/day	(B) cases	HR (95% CI) per 30g/
Oral (C00-C14)	430		1.13 (0.84, 1.52)	185	<b>—</b> 1.42 (0.88, 2.31)
Oesophagus (C15)	412		1.05 (0.78, 1.43)	162	1.02 (0.63, 1.66)
Stomach (C16)	271		— 1.23 (0.84, 1.80)	131	1.24 (0.71, 2.17)
Colorectum (C18-20)†	2416	_ <b>+</b> _	1.01 (0.89, 1.15)	1480	0.98 (0.83, 1.15)
Colon (C18)	1610		0.97 (0.83, 1.13)	1008	0.92 (0.76, 1.12)
Rectum (C19-20)	819	_ <b></b>	1.09 (0.88, 1.36)	480	<b>— —</b> 1.10 (0.82, 1.47)
iver (C22)	245		1.10 (0.74, 1.63)	109 ——	<b>•</b> 0.81 (0.45, 1.44)
Pancreas (C25)	484		0.97 (0.73, 1.29)	267	<b>—</b> 1.11 (0.75, 1.63)
ung (C34)	1632		0.90 (0.77, 1.04)	270	<b>—</b> 1.21 (0.82, 1.78)
in never smokers ‡	210		— 1.15 (0.75, 1.78)		
lalignant melanoma (C43) §	1212	_ <b></b>	1.06 (0.88, 1.27)	922	
reast (C50) ¶	4175	_ <b>-</b>	1.03 (0.93, 1.13)	3309	
ndometrium (C54) ¶	654		0.97 (0.76, 1.23)	569	<b>—</b> 1.12 (0.86, 1.45)
vary (C56) ¶	422	<b>e</b>	0.96 (0.72, 1.30)	334	1.39 (0.98, 1.97)
rostate (C61) \\	4523	- <b>-</b>	1.05 (0.95, 1.15)	2806	1.06 (0.94, 1.19)
idney (C64-65)	621	<b>_</b>	1.02 (0.79, 1.31)	332	0.87 (0.62, 1.22)
ladder (C67)	464		0.97 (0.72, 1.29)	185	0.93 (0.59, 1.46)
ymphatic and hematopoietic tissues (C81-96	6) 1891	<b></b>	1.20 (1.03, 1.38)	1224	1.14 (0.95, 1.36)
Non-Hodgkin Lymphoma (C82-85)	903		1.23 (1.00, 1.52)	610	1.15 (0.89, 1.49)
Multiple Myeloma (C90)	345	<b></b>	1.11 (0.80, 1.56)	218	<b>1</b> .42 (0.92, 2.21)
Leukaemia (C91-C95)	557	<b></b>	1.09 (0.83, 1.42)	336	0.84 (0.60, 1.17)

# S5 Fig. Associations of <u>poultry intake</u> and cancer incidence by cancer site (per 30g/day) when excluding first 2 years of follow-up (A, n = 464,897) and including only never smokers (B, n = 259,040)\*

## CI, Confidence interval; HR, Hazard ratio.

\* Stratified for sex, age group (<45, 45-<50, 50-<55, 55-<60, 60-<65 and ≥65 years) and region (London, Wales, North-West, North-East, Yorkshire and Humber, West Midlands, East Midlands, South-East, South-West, Scotland) and adjusted for age (underlying time variable), ethnicity (4 groups where possible: White, Asian or Asian British, Black or Black British, Mixed race or other, unknown), deprivation (Townsend index quintiles, unknown), qualification (college or university degree/vocational qualification, national examination at ages 17-18, national examination at age 16, other/unknown), employment (in paid employment, receiving pension, not in paid employment, unknown), living with a spouse or partner (yes, no, unknown), height (sex-specific quintiles, unknown), smoking (never, former, current <15 cigarettes/day, current ≥15 cigarettes/day, current unknown amount of cigarettes/day, unknown), physical activity (<10 excess metabolic equivalents, 10-<50 excess metabolic equivalents, ≥50 excess metabolic equivalents, unknown), alcohol intake (none, <1 g/day, 1-<10 g/day, 10-<20 g/day, ≥20 g/day, unknown), total fruit and vegetable intake (<3 servings/day, 3-<4 servings/day, 4-<6 servings/day, ≥6 servings/day, unknown), estimated cereal fibre intake (sex-specific quintiles, unknown), body mass index (sex-specific quintiles, unknown), in women: menopausal status (pre-, postmenopausal, unknown), parity (nulliparous, 1-2, ≥3, unknown), hormone-replacement therapy (never, past, current, unknown) and oral contraceptive pill use (never, past, current, unknown).

† In 13 (Å) and 8 (B) cases of colorectal cancer (C18/20) colon (C18) and rectal cancer (C19-20) diagnoses coincided.

‡ Analyses restricted to never smokers (A: n = 255,431).

§ Additionally adjusted for skin colour (very fair, fair, light olive, dark olive, brown/black, unknown), hair colour (blonde, red, light brown, dark brown, black, other/unknown), skin reaction (get very tanned, moderately tanning, mildly/occasionally tanning, never tanning only burning, unknown), UV protection use (never/rarely, sometimes, most of the time, always, do not go out in the sunshine, unknown), sunburns before age 15 (never, ever, unknown), solarium use (never, >0-2 times/year,  $\geq$ 3 times/year, unknown).

¶ Analyses restricted to women (A: n = 251,268; B: n = 152,209).

 $\land$  Analyses restricted to men (A: n = 213,629; B: n = 106,831).